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ABSTRACT 
Background: Shiga toxin (Stx)-producing enterohemorrhagic Escherichia coli 
(EHEC) are emerging food- and water- borne pathogens and a leading cause of 
acute renal failure in otherwise healthy children. Ribotoxic Shiga toxins are the 
primary virulence factors and are responsible for the potentially lethal EHEC 
complication of hemolytic uremic syndrome (HUS). HUS, defined clinically by 
microangiopathic hemolytic anemia, thrombocytopenia and thrombotic 
microangiopathy which contribute to acute kidney injury or renal failure, is 
associated with significant patient morbidity. No pathogen- or toxin- specific 
therapeutic exists, and antibiotic use is contraindicated. Understanding the 
molecular mechanisms of Stx toxicity could lead to the development of Stx 
specific therapies.  
Hypothesis: Experimental evidence suggests a role for leukocytes in systemic 
Stx2 trafficking and in Stx2 mediated kidney pathology. Cell stress responses, 
such as the ER stress response and ribosomal stress response, are 
  vii
hypothesized to induce apoptosis, and ultimately cell death, contributing to 
kidney injury; however these processes have only been described in vitro.  If 
leukocyte and kidney cell stress responses are playing significant roles in in vivo 
Stx2 kidney injury, then down-regulation of these processes may provide 
therapeutic benefit. 
Results: Mice injected with Stx2 or infected with Stx2-producing bacteria 
developed lethal kidney injury as judged by biomarkers and histopathology.  
Experimentally induced leukopenia did not alter kidney injury in either model, but 
did cause striking increases in the intestinal bacterial colonization which was 
dependent on the presence of Stx2.  No Stx binding capacity was observed for 
either murine or human leukocytes ex vivo. Transcriptional evidence of kidney 
ER stress and apoptotic biomarkers were observed in both models of Stx2-
mediated kidney injury, but down-regulation of these processes did not yield 
therapeutic benefit.  
Conclusions: Contrary to the current disease paradigm, no major role for 
leukocytes in systemic Stx2 trafficking or kidney injury was observed in vivo, but 
a novel role for host immune responses to Stx2 in the control of intestinal 
colonization by Stx2-producing bacteria was identified.  Cell stress and apoptosis 
is induced by Stx2 in vivo but prevention of these is not sufficient to appreciably 
alter organ injury or survival in the murine models.  
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CHAPTER ONE: INTRODUCTION AND BACKGROUND 
Enterohemorrhagic Escherichia coli 
Shiga toxin producing enterohemorrhagic Escherichia coli (EHEC) is an 
emerging food- and water- borne pathogen responsible for 73,000 infections, 
2,168 hospitalizations and 61 deaths in the United States annually (1). First 
recognized as a human pathogen in 1982, EHEC was considered rare (2) until 
1993, when a multi-state outbreak ultimately traced to undercooked hamburgers 
at a fast food chain caused over 700 cases, and four deaths. As of 2002, 8598 
people have been struck ill in the 350 outbreaks that were reported to the CDC 
(3), and data from recent outbreaks suggests that more virulent strains have 
emerged (4).  Infections generally occur seasonally, from May to November, and 
are most often traced to contaminated ground beef or fresh produce (3), though 
the low infective dose of EHEC (5) makes person-to-person transmission 
possible as well (6).  
EHEC has become a global problem, both pathogenically and 
socioeconomically. Thousands were sickened in an outbreak in Sakai City, 
Japan in 1996 from contaminated bean sprouts (7), and an outbreak with a 
related pathogen in Germany in the summer of 2011 infected over 4000 
individuals (8). The German outbreak was further notable, as the source of the 
outbreak remains unresolved (9). Though isolated from clinical samples, the 
pathogen was never isolated from a food vehicle (10), and that the outbreak was 
attributed to several different sources from several different countries over time 
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resulted in economic losses to Spain, Belgium, Bulgaria, France, Portugal, 
Switzerland, The Netherlands and Germany. Despite that all Spanish vegetables 
assayed tested negative for E. coli, it is estimated that the outbreak cost Spanish 
agriculture at least 51 million Euros in losses (9).  
Among the pathogenic hallmarks of EHEC are the abilities to produce 
attaching and effacing lesions (A/E lesions), mediated by the protein intimin (11, 
12), and to produce and secrete Shiga toxins (Stx1, Stx2 and variants). It is the 
Shiga toxin production that represents the pathogen’s primary virulence factor 
(13), and production of these ribotoxins defines the bacterium (14). EHEC 
infection presents as a prodromal hemorrhagic colitis (15) with increasing 
likelihood of complication development in children younger than five years old 
(16). Such complications of EHEC include hemolytic uremic syndrome (HUS), 
which as many as 5-15% of infected individuals will develop (17). 
Hemolytic Uremic Syndrome 
 Hemolytic Uremic Syndrome (HUS) is defined by the triad of 
microangiopathic hemolytic anemia, thrombocytopenia and thrombotic 
microangiopathy, contributing to acute kidney injury or renal failure. Clinically, the 
following criteria are used to define HUS diagnosis: packed-cell volume less than 
30% with evidence of erythrocyte destruction on peripheral-blood smear; platelet 
count less than 150E9/L; and elevated serum creatinine (18-20). Over 90% of 
HUS cases can be associated with EHEC infection, referred to as D+HUS, 
though HUS from infection with Streptococcus pneumonia (SP-HUS) (21, 22), as 
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well as HUS resulting from genetic deficiencies in alternative complement 
regulation (atypical HUS – aHUS) are also observed (22, 23). When D+HUS 
develops, it does so within approximately 7-10 days after intestinal symptoms 
begin (24). The first observed abnormality in most D+HUS patients is 
thrombocytopenia, followed by haemolysis, and finally kidney injury, as 
demonstrated by azotaemia (25). Though some risk factors – such as elevated 
white blood cell count, antibiotic administration and age under 10 years (20, 26) – 
are associated with an increased risk of developing HUS, all EHEC infected 
patients are considered at risk for HUS (25).  
 Significant morbidity is associated with D+HUS-induced kidney injury, with 
up to 12% of patients with D+HUS progressing to end stage renal failure within 
four years, and as many as 25% having long term renal impairment (27, 28). 
D+HUS is, in fact, a leading cause of renal failure in otherwise healthy children. 
That the kidney is such a target in D+HUS is likely due to high expression of the 
Shiga toxin receptor, Gb3, on both glomerular endothelial and tubular epithelial 
cells in humans (29, 30). The observed renal pathology due to D+HUS in patients 
includes cortical necrosis, glomerular thrombosis and congestion, endothelial cell 
swelling, and occasional mesangiolysis (31, 32).  
Described thrombotic microangiopathy in D+HUS patients is associated 
with endothelial damage in arterioles and capillaries, as evidenced by 
detachment of cells from the basement membrane (33); the presence of platelet-
fibrin thrombi in the vascular lumen and the deposition of amorphous material in 
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the subendothelial space is also observed (33) . D+HUS patients demonstrate 
elevated pro-thrombotic (34) plasminogen activator inhibitor 1 activity (35, 36), as 
well as high concentrations of D-dimers (36, 37).  
Symptoms of the central nervous system (CNS), such as seizures, 
dysphasia, and cortical blindness are also often present in D+HUS (32). 
Neurological involvement occurs in 20-50% of children with D+HUS, and 
represents the most life-threatening complication (32, 38, 39). Although the CNS 
complications were notably severe in the 2011 German outbreak, no brain 
microthrombi or evidence of ischemia were observed (40). 
The Shiga Toxins 
 Shiga toxins are AB5 holotoxins that consist of a pentameric B subunit 
noncovalently bound to a monomeric A subunit (41). The five B subunits, each 
with a molecular mass of 7.7 kDa, form a central pore, through which the 
carboxyl terminus of the A subunit, which has a molecular mass of 32 kDa, 
inserts (41). The variants of Stx share structural and functional homology with 
each other and with Shiga toxin produced by Shigella dysenteriae (42); Stx1 and 
Stx2 have about 56% amino acid homology and are antigenically distinct (43). 
EHEC strains that produce Stx2 are, epidemiologically, associated with more 
severe disease (13).  
Lambdoid bacteriophages encode the Shiga toxins within EHEC (44), and 
the stx genes are located in the late gene region, upstream of the lysis cassette. 
The production of the Shiga toxins is regulated by the phages via phage gene 
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promoters, and phage-mediated bacterial lysis is responsible for toxin secretion 
(44-46). The A and B subunits are secreted as fragments into the bacterial 
periplasm, and it is within the periplasm that they assemble into the holotoxin 
(47).  
Toxin binding to its cell surface receptor, Gb3, is mediated by the B 
subunit, whereas the A subunit, which has RNA N-glycosidase activity, is 
responsible for the ribotoxic action. The crystal structure of Stx1B in complex with 
a Gb3 analogue indicates that each B subunit monomer has three trisaccharide-
binding sites (48), which helps explain Stx’s high binding constant for Gb3, which 
on the order of 10-9 M (49). Following Stx binding to Gb3, the toxin is endocytosed 
and  the A subunit is nicked by furin (50). Stx undergoes retrograde transport to 
the Golgi apparatus and then the endoplasmic reticulum (ER) (51), where the 
disulfide bond linking the A1 and A2 fragments is reduced, generating catalytic 
activity. Active Stx then translocates to the cytosol, where it cleaves an adenine 
residue on the α-sarcin loop of 28S ribosomal RNA (52, 53). This cleavage 
prevents elongation factor 1-dependent peptide chain elongation, and thus, leads 
to cessation of protein synthesis (52). 
Available Therapeutics  
 Antibiotic use is contraindicated for O157:H7 EHEC, as it has been 
demonstrated to increase the risk of HUS development by as much as three-fold 
(20), potentially by up-regulating the pathogen’s toxin expression (54). The 
phage encoded Stx is under control of the phage cycle (45), and thus remains 
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un-translated under homeostasis. Such phage quiescence is due to the binding 
of a repressor to the operator sites, which inhibits the action of phage early 
promoters (55). Antibiotic use can trigger the bacterial SOS response (56), which 
leads to the destruction of the repressor and the activation of the late phage 
genes, including the Stx gene (57).  
Anti-motility agents and narcotics are similarly not recommended because 
their use is related to an increased risk of developing HUS and/or HUS with 
neurological complications (26, 39), and, because non-steroidal anti-
inflammatory agents can decrease blood flow to the kidneys (58), their use in 
D+HUS is contraindicated (25). Other forms of therapy found to be ineffective in 
D+HUS patients include: plasma infusion, plasmapharesis, intravenous IgG, 
fibrinolytic agents, antiplatelet drugs, corticosteroids and antioxidants (59-62). 
Interestingly, oral therapy with a Shiga toxin-binding agent, Synsorb Pk, failed to 
attenuate disease severity in children with D+HUS in a randomized, multi-center, 
double-blind, placebo-controlled clinical trial (63). Treatment is therefore limited 
to supportive care, including maintenance of fluid and electrolyte levels, and 
monitoring kidney function and dialysis (9, 64). Parental volume expansion 
before the development of D+HUS is associated with attenuated renal injury 
during HUS (65). 
It is not known why one EHEC infected patient will develop HUS and 
another will not. Prothrombotic abnormalities (19) and degraded plasma von 
Willebrand factor (66) are present in a subset of infected children, however their 
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occurrence does not correlate to whether the child develops HUS, and common 
host prothrombotic alleles similarly do not appear to play major roles in HUS 
development (67). Clinical evidence suggests that vascular injury is already 
occurring by day 4 of illness (19, 68).  
The recent European outbreak of the novel Stx producing E. coli O104:H4 
highlighted the dearth of available therapeutics for this emerging pathogen. 
Food-borne pathogens are responsible for an estimated 76 million illnesses in 
the United States annually (69), and with today’s increasingly global food supply, 
development of an effective treatment for EHEC-mediated HUS is crucial. EHEC 
are non-invasive, with rarely observed bacteremia, and it is well established 
within the field that Stx represents the primary virulence factor responsible for 
complications of EHEC such as HUS (13). An understanding of the molecular 
mechanisms of Stx is thus critical, as it could leave to the development of non-
antibiotic and Stx specific therapies.  
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CHAPTER TWO: IDENTIFYING CRITERIA IN THE STX2 MURINE MODEL 
THAT REPORTS ORGAN INJURY, DISEASE SEVERITY, AND 
THERAPEUTIC EFFICACY  
Introduction 
Though it has been over 20 years since the first recorded US outbreak of 
EHEC, a complete understanding of how EHEC and EHEC produced Stx elicits 
complications such as HUS remains to be clarified. EHEC outbreaks tend to be 
due to unpredictable contamination events and no endemic patient populations 
for the study of EHEC pathogenesis exist. Animal models of Stx2- toxemia are 
thus critical for the elucidation of Stx2-mediated pathology.  
Various model development strategies, including challenge with purified 
toxin(s) or bacterial infection, have been attempted, yet no mouse model, or any 
small animal model, completely replicates the EHEC infection and HUS observed 
in patients. No small animal model of Stx2- toxemia demonstrates all of the 
coagulopathy issues – the microangiopathic hemolytic anemia, 
thrombocytopenia, and thrombotic microangiopathy – that are defining of HUS 
(reviewed in (70)). Mouse models are, nonetheless, vital to the complete 
understanding of Stx pathogenesis that is necessary for Stx- specific therapeutic 
development, as they allow for the examination of many aspects of both EHEC 
disease and HUS.  
Challenge of mice with Stx alone allows for clarification of exactly which 
aspects of EHEC pathology are due to the Stx itself rather than to the bacteria, 
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and the full spectrum of human HUS has been achieved in nonhuman primates 
challenged with purified, LPS-free Stx (71, 72). Mice are more sensitive to Stx2 
than to Stx1, but regardless of toxin used, Stx binds specifically to the epithelial 
cells of cortical tubule and medullary collecting duct (73). In mice challenged with 
radiolabeled Stx2 (125I-Stx2) toxin accumulation occurred in the kidneys more 
than other organs (74) at three, 24 and 48 hours after challenge; however, an 
earlier study identified the nasal turbs as the primary site of 125I-Stx2 distribution 
one hour after murine challenge (75).  It is unlikely that a mouse model with full 
spectrum HUS will be possible without changing the expression pattern of the Stx 
receptor, Gb3, as it has been observed that the murine glomerular endothelial 
cells, unlike their human and non-human primate counterparts, do not produce 
Gb3 (76).  
A previously published mouse model of Stx2- toxemia, in which male 
C57Bl/6J mice received multiple sub-lethal doses of Stx2 (three total, on days 0, 
3 and 6) and no pre-treatments, demonstrated some aspects of HUS, though 
coagulopathy was not observed (77). These animals presented with weight loss 
and 100% lethality, as well as elevated plasma BUN and plasma creatinine at 
euthanasia. Histopathologically, fibrin(ogen) deposition in the glomerular capillary 
loops and swollen subendothelial zones were observed in the kidneys.  
 A limitation of any Stx2 challenge model is that it lacks the bacterial 
component that is present in patients presenting with D+HUS. Mice are, relative 
to humans, fairly resistant to EHEC infection, and murine models typically include 
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stressors intended to decrease colonization resistance (reviewed in (78)). 
Examples of such stressors include pre-treatment with antibiotics (79, 80), germ-
free environments (81), and protein calorie malnutrition (82); host-adapted strains 
also demonstrate increased murine virulence (79, 83). Even with successful 
colonization, however, murine EHEC models do not demonstrate A/E lesions, a 
distinguishing pathogenic characteristic of the bacterium (78, 84, 85). A/E lesions 
are histologically distinguished by the bacterial adherence to and the microvilli 
effacement of the host cell, and they cause prominent cytoskeletal changes, such 
as the formation of actin-rich pedestals directly beneath the adherent bacterium 
(86).  
 The mouse pathogen Citrobacter rodentium is, like EHEC, able to 
generate murine A/E lesions (87), a trait which Mallick et al exploited in the 
creation of a Stx2-producing strain of C. rodentium (88). To create this novel 
bacterium, Mallick et al lysogenized C. rodentium with a Stx2- producing phage 
that also contains a chloramphenicol resistance marker. A Stx2-producing C. 
rodentium strain in which a kanamycin resistance marker was inserted within an 
in frame deletion of the Stx gene - thus eliminating Stx2 production from this 
strain - was used as a control. Mice challenged with the Stx2-producing C. 
rodentium strain developed kidney injury associated with lethality, as evidenced 
by histological changes, as well as proteinuria, hematuria, elevated urine KIM-1 
and elevated plasma BUN at euthanasia (88).  
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Herein, we describe the development of a novel murine Stx2 challenge 
model, in which animals receive two injections of 0.05 ng/g Stx2. The rapid time 
course of this model, though not lacking limitations, allowed for important insights 
into the timing of kidney injury following Stx2 challenge. Also described is the 
introduction of the Stx2-producing C. rodentium model to the Kurosawa 
laboratory. The presence of an enteric infection, that produces Stx2 within the 
intestine, more closely mimics human disease. Use of the two models together 
permits confirmation of key experimental findings and provides comparisons 
when either model is manipulated therapeutically.  
Materials and Methods 
Reagents 
Shiga toxin 2 was purchased from the Phoenix lab at Tufts University 
School of Medicine (Boston, MA). Contaminating LPS removal was performed by 
incubation with polymyxin B-agarose beads (Sigma, St. Louis, MO) and 
confirmed by the Pierce LAL chromogenic endotoxin quantitation kit (Thermo 
Scientific, Rockford, IL). Plasma blood urea nitrogen was assayed using the 
QuantiChrom Urea Assay Kit (BioAssay Systems, Hayward, CA). C. rodentium 
strains were a kind gift from Dr. John Leong (Tufts University School of Medicine, 
Boston, MA).  
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Animal experiments 
Six week old C57Bl/6J mice were purchased from The Jackson 
Laboratory, Bar Harbor, ME. Mice were housed under a 12-hour light-dark cycle 
and allowed access to standard diet and water ad libitum. For the Stx2 model, 
male mice were used, and groups were challenged with either 0.05 ng/g Stx2 or 
saline by intraperitoneal injection on days 0 and 3. Animals were weighed and 
observed daily with periodic phlebotomy. Animals were euthanized upon 
reaching euthanasia criteria, which was defined by a loss of >20% bw or 
behavioral changes. In subsequent experiments, animals were euthanized on 
days 2 or 3, before second toxin injection.  
For Stx2-producing C. rodentium experiments, female mice were used. 
Groups were challenged by oral gavage with 0.45E9-1.4E9 CFU C. rodentium 
with (C.r(+Stx2)) or without (C.r(cntrl)) a Stx2-producing phage. Animals were 
weighed and observed daily with periodic phlebotomy and feces collection for 
colonization confirmation. Animals were euthanized upon reaching euthanasia 
criteria. For all experiments, organs were collected at necropsy and were either 
flash frozen or stored in RNAlater (Ambion, Austin, TX) or 10% neutral buffered 
formalin for downstream processing.  
C. rodentium culture 
Bacteria were grown in LB broth with either chloramphenicol (10 mg/mL) 
only (C.r(+Stx2)) or both chloramphenicol (10 mg/mL) and kanamycin (25 ug/mL) 
(C.r(cntrl)) to an OD600 of 0.75-0.90, which corresponds with ~1E10 CFU.  
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Colonization analysis 
 Feces were mixed with 10 volumes of PBS, homogenized with a sterile 
toothpick and centrifuged for 30 seconds at 4000 RPM. Serially diluted 
supernatants were then plated on LB agar containing either chloramphenicol 
alone (C.r(+Stx2)) or both chloramphenicol and kanamycin (C.r(cntrl)). Following 
overnight incubation at 32°C, colonies were counted . Log CFU/g feces was 
calculated using the following equation: log{[(number of counted colonies) x 
(dilution factor plated)] / [feces mass (g)]}. 
RNA isolation 
Tissues stored in RNAlater were thawed on ice, and tissue was aseptically 
dissected. Tissue was lysed using a 5 mm bead in the Tissue Lyser II for 4 
minutes at 25 Hz (Qiagen, Hilden, Germany) in the presence of buffer RLT plus 
and 1% betamercaptoethanol (Qiagen). RNA was then extracted from tissue 
lysate using the RNeasy plus mini kit and QIAcube (Qiagen) following 
manufacturer’s instructions. RNA concentration was quantified 
spectrophotometrically using the Nano Drop Spectrophotometer (Thermo 
Scientific).  
Reverse transcription 
Total RNA was made into cDNA using the Quantifast RT kit (Qiagen) and 
Thermocycler (Applied Biosystems, Beverly, MA) according to manufacturer’s 
instructions. 250 ng RNA was used for each reverse transcription reaction. 
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Quantitative PCR 
Amplification of cDNA was performed in a Step One Plus qPCR machine 
(Applied Biosystems) using the Quantifast SYBR green PCR kit (Qiagen) 
according to manufacturer’s instructions and 1 uMol/liter of the appropriate 
forward and reverse primer sets (table 1). Each sample was analyzed in 
duplicate. Obtained CT values were normalized as follows: [(2^CTgene) / 
(2^CThousekeeper)] / [total RNA in RT reaction (µg)]. 
Histology 
Slides preparation and PAS staining was performed by the Histology core in the 
Department of Pathology and Laboratory Medicine at the Boston University 
School of Medicine. Representative images are shown. 2-4 animals were 
analyzed per group, and 6 images were analyzed per animal. All images blinded 
prior to analysis, and scores were assigned based on scoring criteria described 
in table 2.  
 
Table 1: Primer pair sequences 
Gene Sequence 
Ngal F: 5’CCCTGTATGGAAGAACCAAGGA3’ 
R: 5’CGGTGGGGACAGAGAAGATG3’ 
Kim1 F: 
5’GGAGATACCTGGAGTAATCACACTG3’ 
R: 5’TAGCCACGGTGCTCACAAGC3’ 
Hprt F:5’TGGGCTTACCTCACTGCTTTC3’ 
R:5’CCTGGTTCATCATCGCTAATCAC3’ 
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Table 2: Scoring criteria for kidney histology images.  
 
Criteria (6 fields 
analyzed per 
animal)  
Score  
Injury foci in low 
magnification  
field (20X):  
 
0  0  
1 per field  1  
2 per field  1  
3 per field  1  
4+ per 
field  
1  
Tubule dilation:  
 
0 per field  0  
1-4 per 
field  
1  
4+ per 
field  
1  
Epithelial cell 
shedding:  
1  
Pyknotic bodies:  1  
Total possible 
Score:  
8  
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Results 
Murine response to Stx2 challenge 
A thorough understanding of Stx2 pathogenesis necessitates the use of a 
low-cost, small animal model. To this end, we began with a purified Stx2 
challenge model, in order to have complete confidence that all observed 
pathology was toxin mediated. Mean survival for Stx2 challenged animals was 
5.6±0.5 days (p<0.001 compared to saline control) (Fig. 1A). Observed mortality 
was accompanied by significant body weight loss beginning on day 3 (p<0.001) 
and continuing with time (Fig. 1B). All challenged mice displayed evidence of 
kidney injury, with significantly elevated plasma BUN within the first 72 hours 
(p<0.001) (Fig. 1C), which corresponded with histological observations (Fig. 2A).   
Kidney injury was further quantified by the presence of increased kidney 
mRNA of injury markers NGAL (89) and KIM1 (90) (p<0.01, p<0.001) at 
euthanasia endpoint (Fig. 1D-E). Kidney injury was focal in nature, and only 
tubular injury was observed (Fig. 2A). Injury foci demonstrated tubule dilation 
with decreasing cellular border, epithelial cell shedding, and pyknotic bodies (Fig. 
2A). Injury observed by histopathological analysis was quantified by blinded 
analysis as described in materials and methods, and kidney score increased with 
time (Fig. 2B, Table 3).  
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Figure 1: Stx2 challenge results in kidney injury associated with lethality. 
A,B: Survival and percent total body weight loss. Mouse weight at day 0 was set 
at 100%. Mean values and standard deviation are shown. n=44 (A) or 25 (B) 
mice for Stx2 group, n=10 mice for saline group. Significance was determined by 
Mantel-Cox and Gehan-Breslow-Wilcoxon tests (A) or repeated measures 
ANOVA with Bonferroni post-test (B). ***p<0.001. C: Measurement of BUN levels 
in plasma. Mean values and standard deviation are shown. n=35 mice for Stx2 
group, n=10 mice for saline group. Significance was determined by repeated 
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measures ANOVA with Bonferroni post-test. *p<0.05, ***p<0.001. D, E: 
Measurement of kidney injury marker gene transcripts in kidneys. Mean values 
and standard deviation are shown. n=5 mice for saline group, n=4 mice for day 2, 
n=12 mice for day 3, n=5 mice for euthanasia endpoint. Significance was 
determined by Kruskal-Wallis test with Dunn’s post-test. *p<0.05, **p<0.01, 
***p<0.001.  
 
 
 
  
  
19
 
Normal Day 3 Endpoint
0
2
4
6
8
Measurement TIme Point
Tu
bu
la
r 
In
jur
y 
Sc
o
re
Normal:
Stx2 
(Day 3):
Stx2
(Euthanasia):
20X 40XA B
 
 
Figure 2: Stx2 challenge results in tubular kidney injury. A: Representative 
PAS stained images of kidneys in Stx2 challenge model. Magnification and time 
of euthanasia is as noted in figure. B: Quantification of kidney injury. n=2 for 
normal, n=2 for Stx2 day 3, n=4 or Stx2 euthanasia endpoint. Six images were 
scored per animal. Images were blinded before analysis.  
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Table 3: Kidney injury scores. 
Sample Number of 
injury foci in 
low 
magnification 
field (0, 1, 2, 3 
or 4) 
Tubule 
dilation with 
decreased 
epithelial 
cell border 
(0, 1 or 2) 
Epithelial 
cell 
shedding 
(0 or 1) 
Pyknotic 
bodies  
(0 or 1) 
Sample 
Total  
(8) 
Challenge 
total (8)  
Normal  1 0.5±0.84 0 0 0 0.5± 
0.24 
0.5±0 
2 0 0.5±0.58 0 0 0.5±0.2
3 
Stx2 
Day 3 
1 0.33±0.82 0.5±0.55 0.17±0.41 0.17±0.41 1.67±0.
24 
0.75±0.59 
2 0 0.33±0.52 0 0 0.33±0 
Stx2 
Endpoi
nt 
1 2±0.89 0.83±0.75 0.67±0.52 0.17±0.41 3.67±.1
89 
4.25±0.8 
2 2.17±1.47 1.83±0.41 0.67±0.52 0 4.67±1.
41 
3 1.17±1.47 1.5±0.55 0.5±0.55 0.33±0.52 3.5±0.7
1 
4 1.83±1.17 1.83±0.41 1±0 0.5±0.55 5.17±1.
18 
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Murine response to Stx2-producing C. rodentium hallenge 
In order to more closely replicate human disease – an enteric infection 
with an A/E lesion-producing bacterium that makes Stx – we utilized a recently 
developed murine model of Stx2-producing C. rodentium infection (88). Animals 
receiving the Stx2-producing strain, hereafter referred to as C.r (+Stx2), 
demonstrated 100% mortality (Fig. 3A), with a mean survival time of 8±0.78 
days. Mortality was accompanied by significant body weight loss beginning on 
day 6 (p<0.05) and continuing with time (Fig. 3B). In contrast, 100% survival was 
observed in animals infected with the non-Stx2-producing strain, hereafter 
referred to as C.r (cntrl), with no significant body weight loss (Fig. 3A-B). All 
infected animals were colonized by day 1 post-challenge (Fig. 3C).  
Kidney injury was observed in all mice infected with C.r (+Stx2), as 
evidenced by significantly elevated plasma BUN by day 7 post challenge 
(p<0.001) (Fig. 3D). Kidney expression of injury markers NGAL and KIM1 were 
significantly elevated by euthanasia endpoint (p<0.01, p<0.001) (Fig. 3E-F). 
Histological analysis of kidneys from infected animals revealed a tubular injury 
pattern only in C.r (+Stx2) infected animals, consistent with that observed in Stx2 
challenge model (Fig. 2A). Quantification of injury demonstrated increased score 
in C.r (+Stx2) infected animals. No evidence of kidney injury was observed in any 
C.r (cntrl) infected animals (Fig. 3D-F).  
  
  
22
0 2 4 6 8 10 12 14
0
20
40
60
80
100
C.r (+Stx2)
C.r (cntrl)
***
Day
Su
rv
iv
al
 
(%
)
0 2 4 6 8 10 12 14
70
80
90
100
C.r (+Stx2)
C.r (Cntrl)
*
***
***
***
Day
bo
dy
 
w
ei
gh
t (
%
)
0 2 4 6 8 10 12 14
0
5
10
C.r (+Stx2)
C.r (cntrl)
*
*
*
**
Day
Co
lo
n
iz
at
io
n
 
(L
o
g 
CF
U/
g)
0 2 4 6 8 10 12 14
0
20
40
60
80
100
C.r (+Stx2)
C.r (Cntrl)) ***
***
Day
B
UN
 
(m
g/
dL
)
C.r (Cntrl) C.r (+Stx2)
0
200
400
600
800 **
Challenge
N
G
AL
 
(re
la
tiv
e 
ex
pr
es
si
o
n
/u
g)
C.r (cntrl) C.r (+Stx2)
0
50
100
***
Challenge
K
IM
1 
(re
la
tiv
e 
ex
pr
es
si
o
n
/u
g)
A B
C D
E F
 
 
Figure 3: Stx2-producing C. rodentium model in mice results in death, 
weight loss and kidney injury. A, B: Survival and percent total body weight 
loss. Mouse weight on day 0 was set at 100%. Mean values and standard 
deviation are shown. n=14 mice for C.r (+Stx2) group, n=10 mice for C.r (cntrl) 
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group. Significance was determined by Mantel-Cox and Gehan Breslow-
Wilcoxon tests (A) and repeated measures ANOVA with Bonferroni post-test (B). 
**p<0.01, ***p<0.001. C: Measurement of colonization with time. n=20 for 
C.r(+Stx2), n=10 for C.r(cntrl). Significance was determined by repeated 
measures ANOVA with Bonferroni post-test. *p<0.05, **p<0.01. D: Measurement 
of BUN levels in plasma. Mean values and standard deviations are shown. n=14 
mice for C.r (+Stx2) group, n=10 mice for C.r (cntrl) group. Significance was 
determined by repeated measures ANOVA with Bonferroni post-test. ***p<0.001. 
E, F: Measurement of kidney injury marker gene transcripts in kidneys. Kidneys 
were harvested upon reaching euthanasia criteria (C.r (+Stx2), days 7-9) or at 
end of experiment (C.r (cntrl), day 14). Mean values and standard deviation are 
shown. n=10 mice per group. Significance was determined by student’s t test. 
**p<0.01, ***p<0.001.  
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Figure 4: Stx2-producing C. rodentium challenge results in tubular kidney 
injury. A: Representative PAS stained images of kidneys in Stx2-producing C. 
rodentium model. Magnification and time of euthanasia is as noted in figure. B: 
Mean histological score assigned to images. Images were blinded prior to 
analysis. n=2 mice per group. Six images were scored per animal.  
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Table 4: Kidney injury scores 
 
Sample Number of 
injury foci in 
low 
magnification 
field (0, 1, 2, 3 
or 4) 
Tubule 
dilation with 
decreased 
epithelial 
cell border 
(0, 1 or 2) 
Epithelial 
cell 
shedding 
(0 or 1) 
Pyknotic 
bodies (0 
or 1) 
Sample 
Total (8) 
Challenge 
total (8)  
DBS771  
(-Stx2) 
1 0.33±0.82 0.17±0.41 0 0 0.5±0.71 0.25±0.35 
2 0 0 0 0 0 
DBS770 
(+Stx2)  
1 1.67±1.51 0.5±0.55 0.83±0.41 0.33±0.52 3.33±0.2
4 
2.42±1.30 
2 0.5±0.84 0.33±0.52 0.67±0.52 0 1.5±0.24 
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Summary and discussion 
 The two mouse models used in the above studies, though not without 
limitations, do present with kidney injury, as observed in D+HUS patients. Thus, 
the models provide for a low-cost, easily manipulated way to study Stx2 induced 
kidney pathogenesis. Additionally, these models allowed for the identification of 
important criteria that reported organ injury and disease severity. When these 
criteria are used in downstream experiments, they will ultimately report on 
therapeutic efficacy as well.  
 That Stx2 caused kidney injury associated with lethality in both models 
was reported by increasing plasma BUN with time, increased kidney mRNA 
expression of injury markers NGAL and KIM1, and histological analysis showing 
focal, tubular kidney injury. NGAL, a molecule normally expressed in a variety of 
adult human tissues, has a binding site for NFκB within its promoter region, and 
was recognized as a kidney injury marker in preclinical transcriptome profiling 
studies, which identified NGAL to be one of the most up-regulated genes in the 
kidney early after AKI in animal models (89). KIM1, a transmembrane protein 
specifically up-regulated in dedifferentiated proximal tubule cells after 
ischemic/nephrotoxic AKI, was identified as a kidney injury marker by preclinical 
subtractive hybridization screens (90).  
To our knowledge, the finding that kidney injury, as evidenced by 
significantly elevated plasma BUN, increased kidney NGAL and KIM1, as well as 
histological parameters, precedes reaching euthanasia criteria by 1-4 days is an 
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important novel finding, that sheds light on the time course of Stx2 induced 
kidney injury. It is important to note, however, that differences in time course 
between the mouse models and patients do exist. Though the Stx2-producing C. 
rodentium model better replicates the time course of kidney injury development in 
patients, which is about 7-12 days after diarrhea onset, both models present with 
kidney injury more rapidly then what is observed clinically.  
The Stx2 murine model confirms and extends some, but not all, of the 
findings of other groups utilizing an injected LPS-free Stx2. While Sauter et al, 
who challenged mice with three 0.05 ng/g Stx2 IP injections only measured 
plasma BUN at euthanasia endpoint, and did not measure kidney mRNA 
expression of NGAL and KIM1 at all (77) , our work provides insight into the 
timing of Stx2 induced lethal kidney kidney injury associated with lethality, as 
described above. Important histological differences were observed in our Stx2 
challenge model and that of Sauter et al. While the kidney injury observed in our 
murine Stx2 model was entirely tubular – demonstrated as dilated tubules with 
decreased epithelial cell border, epithelial cell shedding, and pyknotic bodies – 
Sauter et al observed glomerular pathology, including fibrin(ogen) deposition in 
the glomerular capillary loops. As murine renal expression of the Stx2 receptor 
Gb3 is limited to the tubular epithelium, and is not expressed on the glomerular 
endothelium (76), the observed glomerular pathology observed by Sauter et al 
may be secondary to the Stx2 induced tubular injury and may be due to 
contaminating LPS in the Stx2.  
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Modeling HUS using a combination of Stx2 and Gram negative endotoxin 
such as lipopolysaccharide (LPS) has been described (91), based on the 
hypothesis that LPS from other bacterium within the intestine could possibly 
contribute to the pathogenesis of D+HUS. Though LPS+Stx2 challenge of mice 
does present with thrombocytopenia, as well as hemolysis, microthrombi 
formation, increased plasma BUN, and glomerular pathology – all HUS criteria 
observed in D+HUS patients (92) – the coagulation profile observed in these 
animals is distinct from that observed in D+HUS patients in that it is a 
consumptive disseminated intravascular coagulation (DIC) (93, 94). While both 
D+HUS and DIC present with thrombocytopenia, the underlying mechanisms are 
different. DIC is consumptive, in that plasma fibrinogen and coagulation factor 
levels are markedly decreased in patients with DIC, whereas no changes in 
these parameters are observed in HUS (70).  
The Stx2-producing C. rodentium mouse model of Stx2 induced lethal 
kidney injury introduced by Mallick et al (88) and extended by our work 
represents an important tool in characterizing Stx2 mediated pathology and the 
roles of intestinally located, bacterially produced Stx2. The Stx2-producing C. 
rodentium presents with A/E lesions, and is the first murine bacterial Stx2-
toxemia model to do so (78, 84, 85), and also presents with evidence of kidney 
injury – increasing plasma BUN with time, kidney mRNA expression patterns 
consistent with kidney injury, and histological changes. Murine bacterial models 
of Stx2-toxemia used previously in the field almost always required some sort of 
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pre-treatment in order to induce colonization, symptoms of infection, or both 
(reviewed in (70)), and that the Stx2-producing C. rodentium model does not 
have this requirement is significant. For example, though streptomycin pre-
treated, EHEC challenged CD-1 mice presented with intestinal colonization, no 
renal symptoms were observed unless animals were infected with a host-
adapted strain (79), and though streptomycin and mitomycin pre-treated EHEC 
challenged ICR mice demonstrated neurological symptoms, no obvious kidney 
pathology was observed (80).                                                                                   
It is unlikely that animals in either model die of AKI in the classical sense - 
many of the animals have full bladders at necropsy (data not shown), indicating 
that urine production is still occurring at death. The observed tubular injury 
pattern is distinct from that observed in either non-human primates (72) or 
humans (19), where the injury pattern is largely glomerular. The differences in 
kidney injury pattern may be explained by the lack of endothelial or glomerular 
expression of the Stx2 receptor Gb3 in the mouse (76). Based on the significant 
body weight loss in both models, as well as on the observed tubular pattern of 
injury, we hypothesized that the animals are dying of kidney-injury induced fluid 
loss, rather than from typical kidney failure. This hypothesis is consistent with the 
observed development of polyuria and osmotically dilute urine 48-72 hours after 
murine I.P. injection with 0.225 ng/g Stx2 by Psotka et al (76). However, that 
treatment of Stx2-challenged mice with daily isotonic subcutaneous saline 
hydration did not alter survival or increasing plasma BUN values (data not 
  
30
shown) suggests that dehydration due to tubular epithelial injury was not a major 
contributor to lethality.  It is perhaps most accurate to conclude that the animals 
died with kidney injury, rather than due to it, as injury to other organs were not 
analyzed in this study.  
In summary, despite differences in kidney injury patterns as well as time 
course between our mouse models and patients, the mouse models do provide a 
small-animal model of Stx2 induced kidney injury. The models permit 
measurement of quantifiable criteria of kidney injury, including plasma BUN, 
kidney mRNA expression of injury markers NGAL and KIM1, and histological 
analysis. These criteria will allow for crucial methods of ascertaining therapeutic 
efficacy in downstream experiments.  
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CHAPTER THREE: IDENTIFICATION AND CHARACTERIZATION OF 
LEUKOCYTE CONTRIBUTIONS TO STX2 TOXIN PATHOGENESIS IN VIVO 
Introduction 
 The topic of leukocyte roles in D+HUS pathology is controversial. 
Neutrophilia is observed in patients with D+HUS (95), and kidney biopsies from 
D+HUS patients demonstrate kidney leukocyte infiltration (31, 32), suggesting a 
role for leukocytes. Moreover, non-human primates challenged with Stx2 also 
demonstrate kidney leukocyte infiltration, as well as increased urine chemokine 
protein and kidney chemokine mRNA (72).  
 Though most EHEC infected patients are afebrile when they present in a 
medical setting (20), increased plasma and urine levels of certain cytokines in 
D+HUS patients are also suggestive of a leukocyte role in D+HUS pathogenesis. 
Serum and urine IL-6 has been shown to be elevated in D+HUS patients (96), 
indicating systemic and local production of the pro-inflammatory cytokine. Serum 
levels of the neutrotactic (97) chemokine IL-8 were also found to be significantly 
elevated in D+HUS patients, and were found to correlate with serum α1-
antitrypsin-complexed elastase, a marker of neutrophil degranulation (98); urine 
levels of IL-8 and MCP-1 have also been demonstrated in D+HUS patients (99). 
Finally, when plasma levels of lymphocyte chemokine (100) SDF-1 were 
measured in EHEC infected children, elevated levels were found in the children 
that ultimately progressed to HUS (101).  
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A role for leukocytes in systemic toxin trafficking is less clear. EHEC are 
not invasive, and bacteremia is rare (102), yet Stx has been detected in the 
plasma of EHEC- infected patients in only a single study (103), and 
plasmaphoresis in E. coli O104:H4 infected patients that developed D+HUS did 
not demonstrate a clear therapeutic benefit (104). How Stx leaves the gut and 
arrives at the Gb3 rich renal cells is therefore not well understood. The current 
disease paradigm – that EHEC infection in the gut stimulates gut epithelial cells 
to express IL-8, recruiting neutrophils which pick up the toxin - implicates 
leukocytes in the process of toxin distribution. This paradigm is supported by a 
patchwork of observations including in vitro work and inconsistent clinical 
observations, and has never been rigorously tested. 
Supportive in vitro work of the disease paradigm includes data from Stx2 
challenged intestinal carcinoma cells, which demonstrate increased IL-8 mRNA 
transcription as well as protein secretion with increasing Stx2 dose (105). 
Furthermore, it has been demonstrated that clinical isolates of EHEC placed 
apically to colonic carcinoma cells caused neutrophil migration across the cell 
layer, and also induced IL-8 secretion from these cells (106).  However, these 
works utilized cancer cell lines, and Gb3 upregulation under cancerous conditions 
has been described for many types of cancers (107). The intestinal epithelium of 
the human does not express Gb3 (108, 109), and within the human intestine, Gb3 
expression is limited to Paneth cells, pericryptal myofibroblasts and endothelial 
cells in the lamina propria (110). Interestingly, despite the observed lack of Gb3 
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expression by intestinal epithelial cells, immunohistochemical analysis of human 
intestinal tissue from EHEC patients demonstrated intracellular Stx1 and Stx2 in 
surface and crypt epithelial cells (111), indicating that toxin internalization can 
occur in a non-receptor mediated fashion.  
Shiga toxin binding to human neutrophils has been demonstrated ex vivo 
(112), and, when analyzed by flow cytometry, circulating neutrophils from a 
subset of HUS patients were found to be positive for Stx antigen (113, 114). This 
clinical data was later found to be non-reproducible, however, and earlier Stx 
antigen positive neutrophil observations were attributed to non-specific 
interaction of the Stx antibody with neutrophils (115). Furthermore, it has been 
observed that Stx can bind not only to neutrophils but also to erythrocytes (116), 
blood monocytes (117), and platelets (118).  
Current data in support of the disease paradigm that neutrophils are 
responsible for systemic Stx2 trafficking in D+HUS is thus inconsistent, and at 
times, contradictory. Clinical and non-human primate data is supportive of a 
general role for leukocytes and inflammatory host responses in HUS 
pathogenesis, however, little experimental testing has been done in vivo, and, if 
found to be true, no therapeutic opportunities have been tested. In this next 
section, we describe a series of experiments testing both the role for leukocytes 
in Stx2- induced kidney injury pathogenesis and, further, the Stx2- binding and 
interacting capabilities of both murine and human blood cells. Our identification of 
contrasting host-responses to Stx2- induced kidney injury and C. rodentium 
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colonization highlights the importance of thorough examination of disease 
paradigms.  
 
Materials and Methods 
Reagents 
Stx2 toxin was purchased from the Phoenix lab at Tufts University School 
of Medicine (Boston, MA). LPS was removed by incubation with polymyxin B-
agarose beads (Sigma, St. Louis, MO) and was confirmed with the Pierce LAL 
chromogenic endotoxin quantitation kit (Thermo Scientific, Rockford, IL). Blood 
urea nitrogen levels in the plasma were measured using the QuantiChrom Urea 
Assay Kit (BioAssay Systems, Hayward, CA). Cyclophosphamide monohydrate 
was purchased from Sigma. All antibodies used in kidney neutrophil flow 
cytometry experiments were purchased from BD Pharmingen (San Jose, CA). 
DRAQ5 nuclear dye was purchased from Thermo Scientific (Rockford, IL). 
Citrobacter rodentium, a Gram-negative mouse pathogen, were kindly provided 
by Dr. John M. Leong  (Department of Molecular Biology and Microbiology, Tufts 
University Medical Center, Boston, MA) (88). Protein gel electrophoresis and 
western blot reagents such as NuPAGE LDS sample buffer, NuPAGE Novex 
10% Bis-Tris gels, NuPAGE MOPS SDS running buffer, Novex prestaiend 
protein standard, and NuPAGE transfer buffer were all purchased from Life 
Technologies (Grace Island, NY). Stx2 toxoid and mouse anti-Stx2A antibody 
were received from BEI resources (Manassas, VA). Goat anti-mouse IgG, IgA 
  
35
and IgM-Alexa488 antibodies used in flow cytometry experiments and goat anti-
mouse IgG-IRdye800CW antibody used in western blot experiments were 
purchased from Life Technologies, and LiCOR biosciences (Lincoln, NE), 
respectively. 
Animal experiments 
Six week old C57Bl/6J were purchased from The Jackson Laboratory, Bar 
Harbor, ME. Male mice were used for Stx2 challenge experiments, and were 
housed under a 12-hour light-dark cycle and allowed access to standard diet and 
water ad libitum. Groups were challenged with 0.05 ng/g Stx2 by intraperitoneal 
injection on days 0 and 3, either alone, or six hours following cyclophosphamide 
(2 mg, IP injection). Phlebotomy was performed periodically and/or upon 
reaching euthanasia criteria (>20% bw loss or behavioral changes) for analysis of 
plasma BUN, and animals were weighed and observed daily. In subsequent 
experiments, animals were euthanized on day 3 before second toxin injection. 
Saline challenged animals were euthanized between days 5-12. Upon 
euthanasia, organs were harvested and stored in RNAlater (Ambion, Austin, TX). 
 For C. rodentium challenge experiments, female mice were used and 
were housed as male mice were. Groups were challenged with 0.45E9-1.4E9 
CFU C. rodentium with (C.r (+Stx2)) or without (C.r (cntrl)) a Stx2 phage by oral 
gavage either alone, following cyclophosphamide (2 mg, IP injection), following 
GR1 (250 ug per mouse on days 0 and 3, IP injection) (clone RB6-8C5, BioXCell, 
West Lebanon, NH) or co-treated with Urtoxazumab, a humanized monoclonal 
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anti-Stx2 antibody (Teijin Pharmaceuticals, Tokyo, Japan) (20 µg IP daily through 
day 4) (119). In subsequent experiments, cyclophosphamide treatment was in 
conjunction with co-treatment with Urtoxazumab; in later experiments antibody 
was given at 6 hours or 1 day post challenge. Periodic phlebotomy and feces 
collection were performed and for downstream plasma analysis and colonization 
confirmation, respectively, and animals were weighed and observed daily.  
Kidney neutrophil experiments 
Animals challenged with either Stx2 or saline were euthanized on day 3 
and kidneys were harvested for neutrophil analysis as previously described 
(120), with some modifications. Following capsule removal, kidneys were minced 
with a sterile razor blade into sub-millimeter fragments, and were placed into a 
digestion solution containing 1 mg/ml type IV collagenase (Sigma), 100 µg/ml 
type I DNAse (Sigma) and 5 mM CaCl2. Incubation in the digestion solution 
occurred for one hour at 37°C, with rocking. Digest ion solution was then removed 
by centrifugation, and red blood cells were lysed by incubation with ACK lysis 
buffer (Lonza, Portsmouth, NH) for five minutes on ice. Cells were washed, 
passed through a 40 µm cell strainer, and centrifuged. The pellet was 
resuspended in 8 ml of 40% percoll (GE Healthcare, Little Chalfont, UK), 
overlayed on 3 ml of 70% percoll, and centrifuged for 30 minutes at 700XG at 
room temperature. The cells at the interphase were collected, washed and 
counted using a Beckman Coulter counter (BD, Franklin Lakes, NJ). Cells were 
then blocked with 5 µg/ml rat anti-mouse FcγIII/II receptor (clone 2.4 G2, BD 
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Pharmingen) for twenty minutes on ice, and then stained with 1.25 µg/ml CD45-
FITC (rat monoclonal anti-mouse, clone 30-F11, BD Pharmingen) and 0.5 µg/ml 
Ly6G-PE (rat monoclonal anti-mouse, clone 1A8, BD Pharmingen). Cells were 
washed twice, stained with 12.5 µM DRAQ5 fluorescent probe (Thermo 
Scientific) and immediately read on a FACScalibur (BD).   
Mouse blood or bone marrow Stx2 toxoid and toxin experiments 
For mouse blood and Stx2 toxoid experiments, blood from C57Bl/6J mice 
was collected 9:1 v:v Sodium Citrate and incubated with 500 ng/mL Stx2 toxoid 
for 30 minutes at room temperature. Excess toxoid and plasma were removed by 
centrifugation, and red blood cells were lysed by incubation with ACK red blood 
cell lysis buffer (Lonza) for five minutes on ice. Cells were washed and blocked 
for 20 minutes on ice with BD block and then incubated with 0.5 µg/mL mouse 
anti-Stx2A for 30 minutes on ice. Cells were again washed and then incubated 
with goat anti-mouse IgG, IgA, IgM-Alexa488 on ice for 30 minutes, covered. 
Cells were washed twice and read immediately on the FACScalibur.  
For mouse bone marrow and Stx2 experiments, two tibias and two femurs 
from male C57Bl/6J mice were flushed with 6.8 µm sodium citrate to harvest 
bone marrow cells. Cells were washed, then lysed in ACK red blood cell lysis 
buffer (Lonza), washed, and passed through a 40 µm cell strainer. After two more 
washes, cells, were incubated with 20 ng/ml TNFα for 10 minutes in 37ºC water 
bath and 1000 ng/ml Stx2 was added immediately. Cells were incubated with 
Stx2 for 30 minutes on ice, washed, blocked with BD block and incubated with 
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0.5 µg/ml mouse anti-Stx2A for 30 minutes on ice. Cells were washed, and then 
incubated with 0.5 µg/mL goat anti-mouse IgG, IgA, IgM-Alexa488 for 30 minutes 
on ice, covered. Cells were washed twice more and then read immediately on 
FACScalibur.  
C. rodentium culture 
Bacteria were grown in LB broth with either chloramphenicol (10 mg/mL) 
only (C.r(+Stx2)) or both chloramphenicol (10 mg/mL) and kanamycin (25 ug/mL) 
(C.r(cntrl)) to an OD600 of 0.75-0.90, which corresponds with ~1E10 CFU.  
 
Colonization analysis 
 Feces were mixed with 10 volumes of PBS, homogenized with a sterile 
toothpick and centrifuged for 30 seconds at 4000 RPM. Serially diluted 
supernatants were then plated on LB agar containing either chloramphenicol 
alone (C.r(+Stx2)) or both chloramphenicol and kanamycin (C.r(cntrl)). Following 
overnight incubation at 32°C, colonies were counted . Log CFU/g feces was 
calculated using the following equation: log{[(number of counted colonies) x 
(dilution factor plated)] / [feces mass (g)]}. 
RNA isolation, cDNA preparation and qPCR 
RNAlater stored tissues were thawed on ice, and tissue was aseptically 
dissected. A Tissue Lyser II (Qiagen, Hilden, Germany) was used to lyse kidneys 
in the presence of a 5 mm bead and buffer RLT plus=1% betamercaptoethanol 
for 4 minutes at 25 Hz. RNA extraction from tissue lysate was then performed in 
  
39
the QIA cube using the RNease plus mini kit (Qiagen) according to 
manufacturer’s instructions. RNA concentration was quantified using the Nano 
Drop Spectrophotometer (Thermo Scientific). 250 ng of kidney RNA was made 
into cDNA in the Thermocycler (Applied Biosystems, Beverly, MA) using the 
Quantifast RT kit (Qiagen) according to manufacturer’s instructions. A step One 
Plus qPCR machine (Applied Biosystems) was used to amplify cDNA using the 
Quantifast SYBR green PCR kit (Qiagen) and 1 µMol/liter of appropriate forward 
and reverse primer sets (table 5) according to manufacturer’s instructions. Each 
sample was analyzed in duplicate and obtained CT values were normalized as 
follows: [(2^CTgene) / (2^CThousekeeper)] / [total RNA in RT reaction (µg)]. 
 
Table 5: Primer pairs and sequences 
MOLECULE/GENE PRIMER SEQUENCE 
KC/cxcl1 Forward:  
5’-TCAAGAACATCCAGAGCTTGAAG-3’ 
Reverse:  
5’-GGACACCTTTTAGCATCTTTTGG-3’ 
Mip-2α/cxcl2 Forward: 
 5’-CACCAACCACCAGGCTACAG-3’ 
Reverse:  
5’-CAGTTAGCCTTGCCTTTGTTCA-3’ 
 
Human blood and toxin flow cytometry experiments 
 Human blood was collected by arm draw into EDTA, and then incubated 
with an equal volume of either 1% BSA in PBS or 1000 ng/mL Stx2 final for 30 
minutes at room temperature. Ten volumes of 1X BD FACS lysing solution (BD, 
San Jose, CA) was then added directly to the samples, and samples were 
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incubated for an additional 15 minutes at room temperature. Samples were 
centrifuged to remove red blood cell debris, and pellets were resuspended in 
FACS buffer (0.5% BSA, 0.5 mM EDTA, PBS). Mouse anti-Stx2A (0.5 µg/mL) 
was incubated with the samples for 30 minutes on ice, samples were washed, 
and incubated with goat anti-mouse IgG, IgA and IgM for 30 minutes on ice, 
covered. After an additional wash, samples were read on a FACScalibur  (BD).  
Human blood and toxin western blot experiments 
Human blood was collected by finger stick into 12.5 U heparin and 
centrifuged immediately. Plasma and ~10% of cell pellet were pipetted into a 
fresh tube and mixed well by pipetting up and down. Plasma and cells were then 
diluted to a concentration of ~30% in RPMI with heparin. For experimental and 
negative control groups, diluted plasma and cells were then mixed at a ratio of 
1:1 with either 27 µg/mL Stx2 (experimental) or RPMI (negative control), 
incubated at 37ºC for 30 minutes, and were centrifuged at 1500XG for 10 
minutes. Plasma fractions were transferred to clean tubes, and cell pellets were 
resuspended in a reduction master mix containing LDS sample buffer, 2.5% BME 
and water. Reduction master mix was also added to plasma fractions. For 
plasma+Stx2 and cells+Stx2 groups, diluted plasma and cells were centrifuged 
again at 1500XG, and plasma fraction was transferred to a clean tube. Stx2 (27 
µg/mL) was then added directly to both the plasma fraction and the cell pellet, as 
was reduction master mix. Reduction master mix containing 100 ng BSA was 
also added to Stx2 (27 µg/mL) alone. All samples were boiled for 10 minutes, 
  
41
centrifuged briefly, and separated on a 10% Bis-Tris gel (Life Technologies) for 
45 minutes at 175 V. Following protein gel electrophoresis, gel was transferred to 
a PVDF membrane for 1 hour at 30 V, and the membrane was then blocked in 
Odyssey blocking buffer for 1 hour at RT, with rocking (LiCor technologies, 
Lincoln, NE). The membrane was washed three times for ten minutes each in 
TBST, and then was incubated with mouse anti-Stx2A antibody (0.5 µg/mL) 
overnight at 4 ºC, with rocking. Membrane was once again washed three times, 
and was then incubated with goat anti-mouse IgG conjugated to IRdye800 CW 
(1:10,000) for 1 hour at RT, with rocking. After being washed three more times, 
membrane was then imaged on an Odyssey fluorescent imager (LiCor, Lincoln, 
NE) and results were analyzed using ImageJ software (NIH, Bethesda, MD). In 
subsequent experiments, blood was collected by arm draw, and diluted plasma 
and cells were centrifuged at either 160XG (platelet rich plasma) or 3000XG 
(platelet poor plasma) following incubation with Stx2.  
 
Results 
Kidney chemotactic transcriptional pattern after Stx2 challenge 
 Leukocytes have been speculated to play a role in D+HUS pathogenesis 
in patients. Neutrophilia is observed in D+HUS patients (95) and kidney biopsies 
obtained from D+HUS patients show leukocyte infiltration (31, 32). We 
hypothesized that if leukocytes were playing a role in the kidney injury observed 
in the Stx2 challenge mouse model of Stx2 induced kidney injury, then the 
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kidneys from Stx2 challenged mice would have a transcriptional pattern 
consistent with chemotaxis.  
 Kidneys harvested from Stx2 challenged animals euthanized at day 3 or 
saline control animals were processed for RNA extraction, cDNA preparation and 
qPCR as described in materials and methods. Day 3 was the time point chosen 
to assay for chemokine mRNA expression in Stx2 challenged animals because 
BUN is significantly elevated by day 3. As hypothesized, kidney mRNA 
expression of chemokines KC and mip-2α were significantly elevated when 
compared to saline control (p<0.05, p<0.01) (Fig. 5).  
  
  
43
 
Figure 5: Stx2 challenge results in upregulated kidney mRNA expression of 
chemokines. A: Measurement of kidney mRNA of chemokine KC. n=3 for 
saline, n=7 for Stx2. Significance was determined by student’s t-test. *p<0.05. B: 
Measurement of kidney mRNA of chemokine mip-2α. n=3 for saline, n=5 for 
Stx2. Significance was determined by student’s t-test. **p<0.01.  
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Increased kidney neutrophil number after Stx2 challenge 
 Though increased kidney mRNA expression of neutrotactic chemokines is 
suggestive of increased kidney neutrophils, H&E stains of kidneys from 
challenged mice did not show obvious evidence of leukocyte infiltration at any 
time point analyzed (data not shown). We hypothesized that neutrophil 
recruitment to the kidneys were occurring at levels too low to be detected by 
traditional histology methods, and utilized a flow cytometry method to detect 
kidney neutrophils.  
Fluorescence minus one controls were used to determine appropriate 
gates for each sample (Fig. 6), and the neutrophil population was defined as 
Ly6G+ events within the nucleated (DRAQ5+) CD45+ gate. DRAQ5 nuclear stain 
was used to gate out cellular debris, and anti-CD45 antibody was used to gate on 
leukocytes. Ly6G+ events were normalized to nucleated events,  and, as 
predicted by qPCR data, significantly elevated levels of kidney neutrophils were 
detected on day 3 post challenge as compared to saline control.  
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Figure 6: Fluorescence minus one and gating strategies for assay of kidney 
neutrophils in saline and Stx2 challenged animals. A: Fluorescence minus 
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one and gating strategies for assay of kidney neutrophils in saline challenged 
animals. Unstained samples were used to define DRAQ5+ gate (top), DRAQ5 
only stained samples were used to define CD45+ gate (second row), DRAQ5 and 
anti-CD45-FITC only stained samples were used to define Ly6G+ gate (third 
row). Representative data of three animals is shown. B: Fluorescence minus one 
and gating strategies for assay of kidney neutrophils in Stx2 challenged animals. 
Unstained samples were used to define DRAQ5+ gate (top), DRAQ5 only stained 
samples were used to define CD45+ gate (second row), DRAQ5 and anti-CD45-
FITC only stained samples were used to define Ly6G+ gate (third row). 
Representative data of three animals is shown. 
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Figure 7: Stx2-challenged mice demonstrate elevated number of kidney 
neutrophils. n=3 animals per group. All animals were euthanized on day 3. 
Significance was determined by student’s t-test. *p=0.05.  
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Murine response to cyclophosphamide co-treatment during Stx2 challenge 
The observed chemotactic transcriptional pattern and increased kidney 
neutrophils following murine Stx2 challenge are consistent with a leukocyte role 
in Stx2-induced kidney injury, and we hypothesized that depletion of leukocytes 
by cyclophosphamide co-treatment during Stx2 challenge would alter outcomes. 
Such potentially altered outcomes include previously described criteria of lethal 
kidney injury such as survival, weight loss, plasma BUN, and kidney mRNA 
expression of injury markers NGAL and KIM1.  
 Co-treatment with 2 mg of cyclophosphamide per mouse was performed 
by I.P. injection six hours prior to each Stx2 injection, as described in materials 
and methods. Cyclophosphamide caused decreased white blood cell counts 
(table 6), however, contrary to our hypothesis, mean survival time was 
unchanged regardless of leucopenia (Stx2:4.95±1.15, CP+Stx2: 5.1±0.99) (Fig. 
8A). Leukopenic animals lost slightly more body weight compared to non-
leukopenic animals (Fig. 8B), however, no changes in any kidney injury markers 
were observed (Fig. 8C-E). These data suggest that, in our murine Stx2 
challenge model of Stx2 induced kidney injury, leukocytes are not playing a 
major role.  
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Figure 8: Inducing leukopenia by cyclophosphamide co-treatment does not 
alter outcome in murine Stx2 challenge model. A, B: Survival and percent 
total body weight loss. Body weight at day 0 was set at 100%; mean and 
standard deviation are shown. n=39 (A) or 26 (B) for Stx2 only, n=10 for 
CP+Stx2, n=5 for CP only. C: Measurement of plasma BUN levels with time. 
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Mean levels and standard deviation are shown. n=22 for Stx2 only, n=12 for 
CP+Stx2, n=10 for CP only. D: Measurement of kidney injury marker NGAL gene 
transcript in kidneys. n=12 for Stx2 only, n=4 for CP+Stx2. D: Measurement of 
kidney injury marker KIM1 gene transcript in kidneys. n=12 for Stx2 only, n=3 for 
CP+Stx2.  
 
Table 6: White blood cell counts before and after cyclophosphamide co-
treatment.  n=10 mice for CP+Stx2, n=5 mice for CP only.  
Time 
point 
CP+Stx
2 (K/uL) 
CP only 
(K/uL) 
Day 0 6.63±1.
32 
5.91±1.27 
Day 3 1.45±0.
70 
1.52±0.61 
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Stx2 binding capacity of murine leukocytes and bone marrow cells 
 Though the above data do not support a role for leukocytes in the murine 
Stx2 challenge model of Stx2 induced kidney injury, they do not specifically 
exclude a potential role for leukocytes in systemic Stx2 trafficking. If leukocytes 
are responsible for in vivo systemic toxin distribution, then the leukocytes will 
bind Stx ex vivo. To test this hypothesis, anti-coagulated mouse whole blood was 
incubated with Stx2 toxoid and processed for flow cytometry analysis as 
described in materials and methods. As neutrophilia is described in D+HUS 
patients (95), we also tested the binding capacity of mouse bone marrow cells for 
Stx2, with the hypothesis that newly differentiated, immature leukocytes may also 
play a role in toxin trafficking.  
 Neutrophils and lymphocytes were differentiated from each other by light 
scattering properties (Fig. 9A), and gating on bone marrow cells was as shown 
(Fig. 9B). Contrary to our hypothesis, neither Stx2 toxoid nor Stx2 binding was 
detected for neutrophils or lymphocytes (Fig. 9C-D), or bone marrow cells (Fig. 
9E), respectively. These data do not support a role for leukocytes in systemic 
Stx2 distribution in murine models of Stx2 toxemia.  
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Figure 9: Stx2 toxoid and Stx2 binding to blood neutrophils, blood 
lymphocytes and bone marrow is not detectable by flow cytometry. A: 
Gating strategy for mouse whole blood neutrophils and lymphocytes. 
Representative data from three experiments. B: Gating strategy for mouse bone 
marrow. Representative data from two experiments. C, D: Histogram showing 
Stx2+ events for neutrophils (C) or lymphocytes (D). Shaded peak represents 
background staining; solid line peak represents experimental. Data is 
representative of three experiments. E: Histogram showing Stx2+ events for 
bone marrow cells. Shaded peak represents background staining; solid line peak 
represents experimental. Data is representative of two experiments. 
A B
C D E
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Stx2 interaction capacity of human blood cells 
 Data described above are not supportive of a role for leukocytes in 
systemic Stx2 trafficking in murine models of Stx2 induced kidney injury. 
However, binding of Stx to human neutrophils has been demonstrated ex vivo 
(112). In order to test whether the above results were not due to species 
differences, the Stx2 binding capacity of human neutrophils and lymphocytes 
were assayed by flow cytometry as described in materials and methods. Stx2 
binding capabilities have been demonstrated for human platelets (118), 
monocytes (117), and erythrocytes (116), and the capability of Stx2 to interact 
with the cellular compartment of human blood was assayed by protein gel 
electrophoresis and western blotting.  
 As demonstrated in figure 10A, Stx2 does not interact with the cellular 
compartment of human blood, but rather, after a 30 minute incubation, remains 
with the plasma fraction, as indicated by a band at 35 kDa, consistent with the 
molecular weight of Stx2A (Blood+Stx2). These results were not due to non-
specific protease activity in the cellular portion of human blood, as Stx2 added 
directly to blood cells and assayed demonstrated a band at 35 kDa (Cells+Stx2), 
similar to that observed when Stx2 was added directly to plasma (Plasma+Stx2) 
or ran alone (Stx2). The presence of platelets in the plasma or cellular fraction 
did not alter these results, and Stx2 blotted with the plasma portion regardless of 
whether blood was centrifuged to generate platelet rich plasma or platelet poor 
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plasma (Fig. 10B). Consistently, Stx2 binding to neither human neutrophils nor 
human lymphocytes was detected by flow cytometry (Fig. 10C-D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 10: Stx2 does not interact with the cellular portion of human blood 
and, consistently, Stx2 binding to neither human neutrophils nor human 
lymphocytes cannot be detected by flow cytometry. A: 
varying Stx2 and human blood conditions subjected to
electrophoresis. Stx2 indicates Stx2 run alone; Plasma+Stx2 indicates Stx2 
added directly to human plasma; Cells+Stx2 indicates Stx2 added directly to 
human blood cells; Blood+Stx2 indicates Stx2 incubated with  human whole 
Western blot 
 protein gel 
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of 
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blood; Blood+vehicle indicates vehicle incubated with human whole blood. 
Results are representative of three separate experiments. B: Western blot of 
plasma fraction of human blood following incubation with Stx2 and centrifugation 
to generate either platelet rich plasma or platelet poor plasma. C, D: Histogram 
showing Stx2+ events for neutrophils (C) or lymphocytes (D). Shaded peak 
represents background staining; solid line peak represents experimental.  
 
Murine response to cyclophosphamide co-treatment during C. rodentium 
challenge 
 Data from mice co-treated with cyclophosphamide during Stx2 challenge 
do not support a role for leukocytes in Stx2 induced kidney injury. However, the 
model used for these experiments does not recapitulate the source of Stx2 in 
patients with D+HUS – the intestine. In patients with D+HUS, Stx2 production is 
confined to the gut, as this is the location of the Stx2- producing EHEC infection. 
It is possible that intestinally localized Stx2 production is necessary for any 
observation of leukocyte roles in Stx2 induced kidney injury. We therefore 
decided to induce leukopenia by cyclophosphamide co-treatment during either 
Stx2-producing or non-Stx2-producing C. rodentium infection.  
 Depletion of leukocytes in the Stx2-producing C. rodentium model 
significantly worsened animal lethality in both C.r (+Stx2) and C.r (cntrl) 
challenged animals (p<0.001), though mean lethality was significantly earlier in 
the C.r(+Stx2) group (day 5) than in the C.r (cntrl) group (day 6.2) (p<0.05) (Fig. 
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11A). Leukopenic C.r (+Stx2) challenged animals also had significantly increased 
weight loss compared to both non-leukopenic C.r (+Stx2) challenged animals and 
leukopenic C.r (cntrl) challenged animals beginning on day 1, and continuing with 
time (p<0.05 on day 1) (Fig. 11B).  
The cyclophosphamide co-treatment in combination with the presence of 
Stx2 significantly increased gut colonization by the bacterium both compared to 
non-leukopenic C.r (+Stx2) challenged animals and leukopenic C.r (cntrl) 
challenged animals – log CFU/g was increased in the CP+C.r (+Stx2) group on 
day 1 compared to either the C.r (+Stx2) group or the CP+C.r (cntrl) group 
(p<0.001) (Fig. 11C). As all animals died before alterations in kidney function 
were detected, analysis of what role leukocytes may play in Stx2 induced kidney 
injury could not be made from this experiment (Fig. 11D).  
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Figure 11: Cyclophosphamide co-treatment if C.r(+Stx2) challenged 
animals reduces survival and increases colonization. A,B: Survival and body 
weight loss of cyclophosphamide co-treated C.r(+Stx2) and C.r(cntrl) challenged 
animals. n=19 for C.r(+Stx2), n=10 for CP+C.r(+Stx2), n=5 for CP+C.r(cntrl). 
Significance was determined by Mantel-Cox and Gehan-Breslow-Wilcoxon tests 
(A) or repeated measures ANOVA with Bonferroni post-test (B). * is between 
CP+C.r(+Stx2) and C.r(+Stx20; # is between CP+C.r(+Stx2) and CP+C.r(cntrl). 
*/# p<0.05, **/## p<0.01, ***/### p<0.001. C: Colonization in cyclophosphamide 
co-treated C.r(+Stx2) and C.r(cntrl) challenged animals. n=19 for C.r(+Stx2), 
n=10 for CP+C.r(+Stx2), n=5 for CP+C.r(cntrl). Mean and standard deviation are 
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shown. Significance was determined by repeated measures ANOVA with 
Bonferroni post-test. * is between CP+C.r(+Stx2) and C.r(+Stx2); # is between 
CP+C.r(+Stx2) and CP+C.r(cntrl). ## p<0.01. ***/### p<0.001. D: Plasma BUN 
for cyclophosphamide co-treated C.r(+Stx2) and C.r(cntrl) challenged animals. 
n=19 for C.r(+Stx2), n=10 for CP+C.r(+Stx2), n=5 for CP+C.r(cntrl).  
 
Murine response to Urtoxazumab co-treatment during CP+C.r(+Stx2) challenge 
 That only leukopenic C.r (+Stx2) challenged animals demonstrated 
significantly increased gut colonization indicates that the Stx2 production by 
these bacterium is necessary for the observed phenotype. To test this 
hypothesis, cyclophosphamide co-treatment during C.r (+Stx2) challenge was 
accompanied by co-treatment with Urtoxazumab – a humanized, mouse 
monoclonal antibody to Stx2 that has been shown to rescue EHEC challenged 
mice when given up to 24 hours post infection (119) – given by IP injection daily 
through day 3.  
 Urtoxazumab co-treatment of leukopenic C.r (+Stx2) challenged animals 
significantly extended survival time (5.5 days versus 7.4 days) (p<0.05) (Fig. 
12A) and reduced initial body weight loss, though body weight loss was 
significantly increased compared to C.r(+Stx2) challenge alone by day 4 (p<0.01) 
(Fig. 12B).  Consistent with our hypothesis, Urtoxazumab co-treatment 
successfully abolished the cyclophosphamide-induced colonization increases 
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(Fig. 12 C), and colonization in co-treated animals was significantly (p<0.001) 
lower than in non-co-treated animals as early as day 1 post-challenge.  
 As a late, though not significant, elevation in plasma BUN was observed in 
Urtoxazumab co-treated leukopenic C.r(+Stx2) challenged animals (Fig. 12D), 
kidney mRNA expression levels of injury markers NGAL and KIM1 were 
measured. Both NGAL (Fig. 12E) and KIM1 (Fig. 12F) kidney expression levels 
were lower in co-treated animals. 
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Figure 12: Urtoxazumab co-treatment of leukopenic C.r(+Stx2) challenged 
animals abolishes colonization increases and alters kidney injury 
associated with lethality. A,B: Survival and body weight loss of 
Urtoxazumab+CP+C.r(+Stx2) challenged animals. n=19 for C.r(+Stx2), n=10 for 
CP+C.r (+Stx2), n=5 for Urtox+CP+C.r(+Stx2). Significance was determined by 
Mantel-Cox and Gehan-Breslow-Wilcoxon tests (A) or repeated measures 
ANOVA with Bonferroni post-test (B). * is between Urtox+CP+C.r(+Stx2) and 
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C.r(+Stx2), # is between Urtox+CP+C.r(+Stx2) and CP+C.r(+Stx2). # p<0.05, ** 
p<0.01, ***/### p<0.001. C: Colonization in Urtoxazumab+CP+C.r(+Stx2) 
challenged animals. n=19 for C.r(+Stx2), n=10 for CP+C.r(+Stx2), n=5 for 
Urtox+CP+C.r(+Stx2). Mean and standard deviation are shown. Significance was 
determined by repeated measures ANOVA with Bonferroni post-test. # is 
between Urtox+CP+C.r(+Stx2) and CP+C.r(+Stx2). ###p<0.001. D: Plasma BUN 
of Urtox+CP+C.r(+Stx2) challenged animals. n=19 for C.r(+Stx2), n=10 for 
CP+C.r(+Stx2), n=5 for Urtox+CP+C.r(+Stx2). Mean and standard deviation are 
shown. E: Kidney mRNA expression of injury marker NGAL. F. Kidney mRNA 
expression of kidney injury marker KIM1. Significance was determined by 
student’s t-test. *p<0.05.    
 
Murine response to delayed Urtoxazumab treatment during CP+C.r(+Stx2) 
challenge 
 The observed colonization increases on day 1 post challenge in 
CP+C.r(+Stx2) challenged mice suggests that early pathological events are 
giving rise to the increased colonization. Since Urtoxazumab co-treatment given 
on day 0 was able to abolish the colonization increases in leukopenic C.r(+Stx2) 
challenged animals, we hypothesized that if animals were given delayed 
Urtoxazumab treatment on day 1 post challenge, then we would see an initial 
colonization increase that would be eliminated by day 2.  
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Delayed Urtoxazumab treatment extended survival time slightly in 
leukopenic animals when compared to non-treated leukopenic animals (5.5±0.85 
versus 6.33±0.58)(n.s.), however, no colonization changes were observed until 
late time points (days 6-7) (Fig. 13A). Colonization was significantly increased as 
compared to un-treated, non-leukopenic C.r(+Stx2) challenged animals on days 
1-5 (p<0.001), but was significantly lower than un-treated leukopenic C.r(+Stx2) 
animals on day  6 (p<0.001),  and was also significantly lower than un-treated, 
non-leukopenic C.r(+Stx2) animals on day 7 (p<0.001) (Fig. 13A).  
 The results of delayed Urtoxazumab treatment on day 1 post-challenge 
are consistent with the hypothesis that the Stx2 induced pathology mediating the 
colonization increases occurs before day 1. In order determine how early this 
pathology takes place, animals were given delayed Urtoxazumab treatment six 
hours after CP+C.r(+Stx2) challenge. Urtoxazumab treatment at six hours post-
challenge worsened lethality (5.5±0.85 versus 4.4±0.79)(p<0.05); however, 
delayed Urtoxazumab treatment at six hours was able to eliminate the observed 
colonization increases in CP+C.r(+Stx2) challenged mice (Fig. 13B). Not only 
were colonization levels in leukopenic animals receiving Urtoxazumab treatment 
at six hours post-challenge significantly lower than those observed in un-treated 
leukopenic C.r(+Stx2) challenged animals (p<0.001 days 1-5, p<0.01 day 6), but 
colonization levels in leukopenic, six hours treated animals were also significantly 
lower than those observed in non-leukopenic, un-treated C.r(+Stx2) challenged 
animals at early time points (p<0.05 on days 1 and 3, p<0.01 on day 2). Taken 
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together, these data indicate that Stx2 induced pathological changes mediating 
the increased colonization observed in CP+C.r(+Stx2) challenged animals take 
place early, between six and 24 hours post challenge.  
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Figure 13: Stx2 induced pathological changes mediating increased 
colonization in CP+C.r(+Stx2) challenged animals take place between six 
and 24 hours post-challenge. A: Survival (left) and colonization (right) of 
CP+C.r(+Stx2) challenged animals given delayed Urtoxazumab treatment on day 
1 post-challenge. n=19 for C.r(+Stx2), n=10 for CP+C.r(+Stx2), n=3 for Urtox(day 
1)+CP+C.r(+Stx2). Significance was determined by Mantel-Cox and Gehan-
Breslow-Wilcoxon tests (left) and by repeated measures ANOVA with Bonferroni 
post-test (right). * is between Urtox(Day1)+CP+C.r(+Stx2) and C.r(+Stx2), # is 
between Urtox(Day1)+CP+C.r(+Stx2) and CP+C.r(+Stx2). **p<0.01, 
***/###p<0.001. B: Survival (left) and colonization (right) of CP+C.r(+Stx2) 
challenged animals given delayed Urtoxazumab treatment at six hours post-
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challenge. n=10 for C.r(+Stx2), n=10 for CP+C.r(+Stx2), n=7 for 
Urtox(6hrs)+CP+C.r(+Stx2). Signifiance was determined by Mantel-Cox and 
Gehan-Breslow-Wilcoxon tests (left) and by repeated measures ANOVA with 
Bonferroni post-test (right). * is between Urtox(6hrs)+CP+C.r(+Stx2) and 
C.r(+Stx2), # is between Urtox(6hrs)+CP+C.r(+Stx2) and CP+C.r(+Stx2). */# 
p<0.05, **/## p<0.01, ***/### p<0.001.  
 
Murine response to Urtoxazumab co-treatment during C.r(+Stx2) challenge 
 That delayed Urtoxazumab treatment at either six hours or 24 hours post-
challenge was unable to lower mortality compared to un-treated CP+C.r(+Stx2) 
challenged animals was surprising, as delayed treatment with this antibody 24 
hours post challenge has been shown to significantly extend survival in an EHEC 
challenge mouse model (119). To address the efficacy of this antibody against 
kidney injury associated with lethality in C.r(+Stx2) challenged animals, 
C.r(+Stx2) challenged animals were co-treated with Urtoxazumab on day 0.  
 Urtoxazumab co-treatment slightly lowered mortality (7.8±0.77 days in 
untreated animals; 8.7±2.52 days in co-treated animals) (n.s.) (Fig. 14A), 
however, weight loss was not significantly altered (Fig. 14B). Consistent with 
observations made in leukopenic, Urtoxazumab treated C.r(+Stx2) challenged 
animals, Urtoxazumab co-treatment reduced C. rodentium colonization, and 
colonization was significantly reduced at two time points (p<0.001 on 3, p<0.01 
on day 7) (Fig. 14C). 
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No markers of kidney injury were altered in co-treated animals when 
compared to non-treated animals – plasma BUN, as well as kidney mRNA levels 
of NGAL and KIM1  were all significantly elevated when compared to C.r(cntrl) 
challenged animals (Fig. 14D-E). These data suggest that Urtoxazumab co-
treatment is not protective against Stx2 mediated lethal kidney injury in this 
model.  
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Figure 14: Urtoxazumab co-treatment of C.r(+Stx2) challenged animals is 
not protective against Stx2 mediated kidney injury associated with lethality. 
A, B: Survival and percent body weight loss of C.r(cntrl), C.r(+Stx2) and 
Urtoxazumab co-treated C.r(+Stx2) challenged animals. n=10 for C.r(cntrl), n=19 
for C.r(+Stx2), n=3 for Urtoxazumab+C.r(+Stx2). C: Colonization levels of 
C.r(cntrl), C.r(+Stx2) and Urtoxazumab co-treated C.r(+Stx2) challenged animals. 
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n=10 for C.r(cntrl), n=19 for C.r(+Stx2), n=3 for Urtoxazumab+C.r(+Stx2). 
Significance was determined by repeated measures ANOVA with Bonferroni 
post-test and is comparing Urtoxazumab+C.r(+Stx2) and C.r(+Sx2). **p<0.01, 
***p<0.01. C: Plasma BUN of C.r(cntrl), C.r(+Stx2) and Urtoxazumab+C.r(+Stx2) 
challenged animals. n=10 for C.r (cntrl), n=19 for C.r(+Stx2), n=3 for 
Urtoxazumab+C.r(+Stx2). Significance was determined by repeated measures 
ANOVA with Bonferroni post-test, and is comparing Urtoxazumab+C.r(+Stx2) 
and C.r(+Stx2). **p<0.01. D, E: Kidney mRNA expression levels of kidney injury 
markers NGAL (D) and KIM1 (E). n=10 for C.r(cntrl), n=10 for C.r(+Stx2), n=3 for 
Urtoxazumab+C.r(+Stx2). Significance was determined by Kruskal-Wallis test 
with Dunn’s multiple comparison test, and is comparing both groups to C.r(cntrl). 
*p<0.05, ***p<0.001.  
 
Murine response to GR1 co-treatment during C.r(+Stx2) challenge 
 Though cyclophosphamide successfully depletes the leukocyte population 
in mice, it is not specific for hematopoietic cells, and cells of the intestinal 
epithelium are also affected by cyclophosphamide (121). The above experiments 
showing increased colonization in CP+C.r(+Stx2) challenged mice thus do not 
allow for discerning whether the reduction in infiltrating leukocytes, the alteration 
of intestinal host immune-responses, or both are mediating the observed 
colonization increases.  
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In order to more specifically alter the infiltrating leukocyte population in 
these animals, C.r(+Stx2) challenged mice were rendered leukopenic by GR1 co-
treatment, as described in materials and methods. The RB6-8C5 clone was 
chosen because it recognizes both Ly-6G and Ly-6C. Though Ly-6G is found 
only on neutrophils, Ly-6C is expressed on neutrophils, dendritic cells and 
subsets of monocytes, macrophages and lymphocytes (122), and use of the 
RB6-8C5 clone is expected to deplete a broader range of leukocytes. Both 
neutrophils and lymphocytes remain depleted two days after a single dose (table 
7).  
 Depletion of leukocytes using GR-1 significantly increased mortality for 
both C.r(+Stx2) and C.r(cntrl) challenged mice (C.r(+Stx2) p<0.01, C.r(cntrl) 
p<0.01) (Fig. 15A), and also increased weight loss (Fig. 15B). However, the 
increased colonization observed in CP+C.r(+Stx2) challenged animals was not 
reproduced in GR1+C.r(+Stx2) challenged animals (Fig. 15C), indicating that 
altered intestinal host immune-responses are likely mediating the increased 
colonization observed in CP+C.r(+Stx2) challenged animals.  
 Plasma BUN at various time points as well as kidney mRNA expression of 
injury markers NGAL and KIM1 at endpoint euthanasia were assayed as markers 
of kidney function. No significant differences in plasma BUN were observed 
between GR1+C.r(+Stx2) and C.r(+Stx2) challenged animals (Fig. 15D), nor 
were differences in kidney NGAL or KIM1 expression (Fig. 15E-F). These data 
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suggest that the absence of neutrophils and lymphocytes in the Stx2-producing 
C. rodentium murine model did not alter Stx2 induced kidney injury.  
 
Table 7: Neutrophil and lymphocyte concentration in blood of mice given 
250 ug GR1. n=3 mice.  
 Neutrophils 
(K/uL) 
Lymphocytes 
(K/uL) 
Day 
0: 
0.83±0.23 6.36±1.72 
Day 
2: 
0.06±0.03 2.54±0.64 
Day 
3: 
0.17±0.06 5.64±2.01 
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Figure 15: GR1 co-treatment of C.r(+Stx2) challenged animals does not 
phenocopy observed colonization changes in CP+C.r(+Stx2) animals, and 
does not protect against kidney injury associated with lethality. A,B: 
Survival and percent body weight of C.r(+Stx2), C.r(cntrl), GR1+C.r(+Stx2) and 
GR1+C.r(cntrl) challenged animals. n=19 for C.r(+Stx2), n=10 for C.r(cntrl), n=5 
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for GR1+C.r(+Stx2), n=5 for GR1+C.r(cntrl). Significance was determined by 
Mantel-Cox and Gehan-Breslow-Wilcoxon tests (A) or repeated measures 
ANOVA with Bonferroni post-test (B). * is comparing GR1 versus un-treated, # is 
comparing GR1 co-treated C.r(+Stx2) or C.r(cntrl). */#p<0.05, **/##p<0.01. C: 
Mean colonization for challenged animals. n=19 for C.r(+Stx2), n=10 for 
C.r(cntrl), n=5 for GR1+C.r(+Stx2), n=5 for GR1+C.r(cntrl). D: Mean plasma BUN 
for challenged animals. n=19 for C.r(+Stx2), n=10 for C.r(cntrl), n=5 for 
GR1+C.r(+Stx2), n=5 for GR1+C.r(cntrl). E, F: Kidney expression of injury 
markers NGAL and KIM1. n=10 for C.r(+Stx2), n=10 for C.r(cntrl), n=5 for 
GR1+C.r(+Stx2), n=5 for GR1+C.r(cntrl). Significance was determined by 
Kruskal-Wallis test with Dunn’s multiple comparisons test and is compared 
against C.r(cntrl) unless otherwise indicated. *p<0.05, ***p<0.001.  
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Summary and discussion 
 These studies demonstrate experimentally that, though leukocytes are not 
playing major roles in Stx2 induced murine kidney injury and are likely not 
responsible for systemic Stx2 distribution in vivo, host immune-responses to Stx2 
are important for colonization control of Stx2-producing bacteria.  
The finding that the kidneys of Stx2 challenge mice demonstrate 
increased mRNA expression of chemokines KC and MIP-2α and increased 
neutrophils is consistent with clinical and animal model data. IL-8 is increased in 
both the serum (98) and urine (99) of D+HUS patients, suggesting systemic and 
local production of the chemokine, and kidney leukocyte infiltration has been 
observed (31, 32). Renal leukocyte infiltration has also been observed in non-
human primates challenged with Stx2, as has increased kidney chemokine 
mRNA and urine chemokine protein (72). Neutrophilia and lymphocytosis have 
been described previously in other mouse models of Stx2 induced kidney injury 
(77), and CCR1-/- mice, which lack the chemokine receptor CCR1, demonstrate 
decreased mortality, neutrophilia and renal neutrophil infiltration after Stx2 
challenge compared to wild-type Stx2 challenged mice (123).  
That mice rendered leukopenic by cyclophosphamide co-treatment were 
not rescued from lethal Stx2 challenge was therefore surprising. 
Cyclophosphamide co-treated Stx2 challenged mice had mortality rates similar to 
those of non-leukopenic Stx2 challenged animals, and kidney injury markers 
plasma BUN and kidney mRNA levels of NGAL and KIM1 were also unchanged; 
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similar results were observed when Stx2-producing C. rodentium challenged 
mice were co-treated with GR1. Such data differs from that of Fernandez et al, 
who found that neutrophil depletion throughout Stx2 challenge significantly 
reduced mortality (124). An important difference between the two studies, 
however, is the original mortality rate of Stx2 challenge. Whereas the model of 
Stx2 induced kidney injury used by Fernandez et al used a single 1 ng Stx2 per 
mouse injection (not adjusted to body weight) and demonstrated only 50% 
lethality, our model used two 1 ng Stx2 per 20 g body weight injections, adjusted 
to body weight, and demonstrated 93% lethality. The less severe model may 
have allowed for observations of mortality differences that were unobservable in 
our more severe model.  
Our data analyzing the Stx2 binding and interaction properties of mouse 
and human blood is inconsistent with the EHEC paradigm that neutrophils are 
responsible for systemic toxin distribution in vivo. Stx2 toxoid and Stx2 binding to 
mouse blood leukocytes and bone marrow cells, respectively, could not be 
detected by flow cytometry, and repeating the experiment with human blood 
yielded similar results. When analyzed by western blot, Stx2 interacted with only 
the plasma fraction of human blood, and not the cellular fraction. These data are 
consistent with observed plasma Stx2 concentration increases following murine 
challenge with EHEC (119), as well as with Geelen et al’s finding that clinical 
data demonstrating Stx2-antigen-positive neutrophils was non-reproducible 
(115). Though Stx2 induced endothelial damage has also been attributed to 
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leukocytes (125, 126), the animal models utilized in this study did not present 
with any coagulopathy associated with endothelial damage, and ascertaining 
what roles neutrophils play in D+HUS endothelial damage was thus not possible.  
The observed colonization increases in cyclophosphamide co-treated 
Stx2-producing C. rodentium challenged mice were perhaps the most startling of 
the present study. The striking colonization increase after cyclophosphamide co-
treatment of C. rodentium challenged animals is a novel finding that is suggestive 
of an important role for the host immune-response to Stx2. The toxin’s role in 
increased colonization in cyclophsphamide co-treated animals is clear, as only 
the Stx2-producing C. rodentium strain demonstrated increased colonization 
during cyclophosphamide co-treatment; the abolished colonization increase with 
Urtoxazumab co-treatment highlights this point. An important limitation of this 
work, however, is that untreated control animals were not ran in parallel to the 
Urtoxazumab treated animals. Moreover, lack of isotype antibody control treated 
animals complicates interpretation of this data.  
Though a role for passive or active immunity against Stx2 in intestinal 
colonization by Stx2-producing bacterium has been previously established (84), 
the finding that delaying antibody treatment by one day was unable to rescue 
increased colonization is original and speaks to the importance of early events in 
Stx2-producing bacterium intestinal pathology. The inability of Urtoxazumab co-
treatment to rescue Stx2-producing C. rodentium challenged animals from lethal 
kidney injury differs from the findings of Yamagami et al, who found that 
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Urtoxazumab co-treatment of EHEC challenged animals resulted in 100% 
survival (119). Importantly, EHEC, unlike C. rodentium, do not make A/E lesions 
in mice (78, 84, 85, 87). It is therefore possible that the ability of our Stx2-
producing C. rodentium strain to make A/E lesions allowed for increased Stx2 in 
the vasculature, increased Stx2 reaching the kidney, and thus, ameliorated any 
protective effects of Urtoxazumab. An important limitation to the above 
experiment was the small sample size used (n=3). It is possible that differences 
between groups may have been observed if a larger sample size was used, or if 
an untreated control group was ran in parallel. Urtoxazumab co-treatment of 
animals challenged by Stx2 was protective against lethal kidney injury (data not 
shown).   
The findings presented herein – that leukocyte depletion prior to murine 
Stx2 challenge does not rescue Stx2 induced kidney injury, that neither Stx2 
binding nor interaction to mouse or human white blood cells can be detected, and 
that altering the intestinal host immune-response during Stx2-producing C. 
rodentium challenge causes staggering colonization increases – yield valuable 
insights into the roles of host-immunity during D+HUS. Not only do these data 
challenge the prevailing disease paradigm of systemic Stx2 distribution, it also 
provides for an alternative role for immunity in D+HUS – a role during the EHEC 
infection stage. Further studies on host immune-response mechanisms of 
controlling Stx2-producing bacterial colonization could provide potential 
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pathogen-specific therapeutic targets for tackling this potentially lethal, foodborne 
pathogen.  
 
CHAPTER FOUR: CHARACTERIZATION AND DOWNREGULATION OF 
KIDNEY CELL STRESS RESPONSES IN VIVO 
Introduction 
 Though the enzymatic action of Stx is well characterized (52, 53), the 
exact mechanism of how the inhibition of protein synthesis gives rise to cell 
death, and ultimately organ dysfunction, remains to be elucidated. Accumulating 
evidence suggests that cell stress pathways, such as the ER stress pathway and 
the ribosomal stress response (RSR), may play a role in Stx2 induced cell death, 
by causing apoptosis. If cell stress and apoptotic pathways are indeed 
contributing to cell death and organ dysfunction in vivo, then these pathways may 
represent a therapeutic target.  
 Both in vitro and in vivo data suggest a role for apoptosis in Stx induced 
cell death. Challenge of the human myelogenous leukemia cell line THP-1 with 
Stx1 results in caspase-8 activation, which leads to processes consistent with the 
formation of the apoptosome, such as cleavage of Bid and mitochondrial release 
of cytochrome c into the cytoplasm (127). Human renal cortical epithelial cells in 
primary culture challenged with either Stx1 or Stx2 demonstrate DNA 
fragmentation, indicating apoptotic processes (128), and when renal cortices 
from EHEC infected mice, as well as from children with D+HUS, were analyzed 
for apoptotic changes, dUTP nick end labeled (TUNEL) cells were observed (30). 
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 The requirement for retrograde transport from cell membrane to the ER for 
toxic activity is shared by many AB5 holotoxins (129, 130).  Following binding to 
Gb3, Stx undergoes retrograde transport to first the Golgi apparatus and then the 
ER (51), and use of brefeldin A to inhibit formation of functional Golgi complexes 
abolishes Stx1-induced DNA fragmentation in THP-1 cells (131). Taken together, 
these data suggest a role for Stx retrograde transport to the ER in Stx induced 
apoptosis. Moreover, THP1 cells challenged with Stx1 demonstrate 
transcriptional and translational changes consistent with the unfolded protein 
response (UPR), ER stress, and apoptosis (132). However, data indicating a role 
for the UPR and ER stress in Stx2 mediated cell death is limited to in vitro 
studies, and has never been demonstrated in vivo.  
 There is evidence to suggest that the toxin’s mechanism of action – 
cleavage of an adenine residue on the α-sarcin loop of 28S ribosomal RNA (52, 
53) – results in a distinct signaling response known as the ribosomal stress 
response (RSR). First described by Iordanov et al in 1997, the RSR is defined as 
both the induction of C-Fos and C-Jun mRNA and the activation of the stress 
activated protein kinase (SAPK) JNK following 28S rRNA damage (133), with 
downstream effects including cytokine production and apoptotic signaling. Up-
regulation of TNFα gene expression and nuclear translocation of NF-κB and AP-1 
following Stx1 challenge of THP1 cells (134) are consistent with activation of the 
RSR, and up-regulation of C-Fos and C-Jun mRNA as well as 
monophosphorylation of the JNK substrate JUN following Stx1 challenge of an 
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intestinal epithelial cell line has also been demonstrated (135). Inhibition of the 
MAP3K ZAK - which is hypothesized to be the MAP3K that transduces the signal 
from the damaged ribosome to the SAPK - during Stx2 challenge of either 
intestinal epithelial cells or African green monkey kidney epithelial cells (Vero 
cells) blocked SAPK activation and up-regulation of IL-8 and improved cell 
viability (136).  
 If cell stress pathways and apoptosis are playing roles in Stx2 mediated 
cell death and organ dysfunction in vivo, then it is expected not only that markers 
of these processes will be present in the kidney, but also that down-regulation of 
these processes will have a therapeutic benefit, either by preventing kidney injury 
or by rescuing animals. Herein, we describe the identification and 
characterization of kidney mRNA transcriptional patterns consistent with the ER 
stress response and apoptosis in two models of Stx2 induced kidney injury. In 
addition, we describe a series of experiments designed to observe the effects of 
down-regulating these processes, utilizing molecules previously published to 
down-regulate the specific process – including anti-coagulant and cyto-protective 
Activated Protein C (APC) (137), the kinase inhibitor Nilotinib (136, 138), and the 
pan-caspase inhibitor Z-Val-Ala-DL-Asp-fluoromethylketone (Z-VAD-FMK) (139) 
- on both cell stress and apoptotic transcriptional patterns and on lethal kidney 
injury.  
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Materials and Methods 
Reagents 
 Shiga toxin 2 was purchased from the Phoenix lab at Tufts University 
School of Medicine (Boston, MA). Contaminating LPS removal was performed by 
incubation with polymyxin B-agarose beads (Sigma, St. Louis, MO) and 
confirmed by the Pierce LAL chromogenic endotoxin quantitation kit (Thermo 
Scientific, Rockford, IL). Activated Protein C (APC) was a kind gift from 
Kaketsuken (Kumamoto, Japan) and Z-VAD-FMK was purchased from Bachem 
(Torrence, CA). Nilotinib was kindly provided by Dakshina M. Jandhyala from 
Tufts University School of Medicine (Boston, MA). RNAlater was purchased from 
Ambion (Austin, TX), and Buffer RLT plus, RNeasy plus mini kit, Taq PCR 
master mix, Quantifast RT kit, and Quantifast SYBR green PCR kits were all 
purchased from Qiagen (Hilden, Germany). PstI restriction enzyme and 
accompanying buffers were purchased from Thermo Scientific.  
C. rodentium culture 
 Bacteria was grown in LB broth with either chloramphenicol (10 mg/mL) 
only (C.r(+Stx2)) or both chloramphenicol (10 mg/mL) and kanamycin (25 ug/mL) 
(C.r(cntrl)) to an OD600 of 0.75-0.9, which corresponds with approximately 1E10 
CFU.  
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Animal experiments 
 Six week old C57Bl/6J mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Mice were housed under a 12-hour light-dark cycle 
and allowed access to standard diet and water ad libitum. For the Stx2 model, 
male mice were used, and groups were challenged with either 0.05 ng/g Stx2 or 
saline by intraperitoneal injection on days 0 and 3. In subsequent experiments, 
20 µg APC,625 µg Nilotinib, 125 µg ZVAD, or 20 µg APC+125 µg ZVAD was 
given daily through day 3 by IP injection in conjunction with Stx2. Animals were 
weighed and observed daily with periodic phlebotomy. Animals were euthanized 
on either day 3 (before second Stx2 injection) or upon reaching euthanasia 
criteria. Saline challenged control animals were euthanized between days 5-7. 
 For Stx2-producing C. rodentium experiments, female mice were used, 
and groups were challenged by oral gavage with approximately 0.45E9-1.4E9 
CFU C. rodentium with (C.r(+Stx2)) or without (C.r(cntrl)) a Stx2- producing 
phage. Animals were weighed and observed daily with periodic phlebotomy and 
occasional feces collection for colonization confirmation. For APC experiments, 
animals were challenged as described above, with 20 µg APC given by IP 
injection through day 5. Animals were euthanized upon reaching euthanasia 
criteria. 
 For all animal experiments, organs were collected at necropsy and were 
either flash frozen or stored in RNA later or 10% neutral buffered formalin for 
downstream processing.  
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Colonization analysis 
 Feces were mixed with 10 volumes of PBS, homogenized with a sterile 
toothpick and centrifuged for 30 seconds at 4000 RPM. Serially diluted 
supernatants were then plated on LB agar containing either chloramphenicol 
alone (C.r(+Stx2)) or both chloramphenicol and kanamycin (C.r(cntrl)). Following 
overnight incubation at 32°C, colonies were counted . Log CFU/g feces was 
calculated using the following equation: log{[(number of counted colonies) x 
(dilution factor plated)] / [feces mass (g)]}. 
RNA isolation, reverse transcription and qPCR 
 Tissues stored in RNAlater were thawed on ice, and tissues were 
aseptically disscted. Tissues were lysed using a 5 mm steel bead in the Tissue 
Lyser II (Qiagen) for 4 minutes at 25 Hz in the presence of buffer RLT plus and 
1% betamercaptoethanol.RNA was then extracted from the tissue lysate using 
the RNeasy plus mini kit and QIAcube (Qiagen) according to manufacturer’s 
instructions. RNA concentration was quantified spectrophotometrically using the 
Nano Drop Spectrophotometer (Thermo Scientific). Total RNA was made into 
cDNA using the Quantifast RT kit and Thermocycler (Applied Biosystems, 
Beverly, MA) according to manufacturer’s instructions. Either 250 ng or 2 µg RNA 
was used for each reverse transcription reaction. Amplification of cDNA was 
performed in a Step One Plus qPCR machine (Applied Biosystems) using the 
Quantifast SYBR green PCR kit according to manufacturer’s instructions and 1 
µMol/liter of the appropriate forward and reverse primer sets (table 8). Each 
  
85
sample was analyzed in duplicate. Obtained CT values were normalized as 
follows: [{2^CTgene)/{2^CThousekeeper)]/[total RNA in RT reaction (µg)].  
 
Table 8: primer pair sequences.  
Xbp1 F: 5’AAACAGAGTAGCAGCTCAGACTGC3’ 
R: 3’ATCTCTAAGACTAGGGGCTTGGT3’ 
ERdj4 (HSP40) F: 5’AGGAACCTGGGAGCTTGACTA3’ 
R: 5’ACACATGACGTGCTTGGAATG3’ 
Bcl2 F: 5’TTCTTTGAGTTCGGTGGGGTC3’ 
R: 5’TGCATATTTGTTTGGGGCAGG3’ 
Dr5 F: 5’TTCCAGTAGTGCTGCTGATTGG3’ 
R: 5’CAAACGCACTGAGATCCTCCT3’ 
Ddit3 (CHOP) F: 5’AGTTATCTTGAGCCTAACACGTCG3’ 
R: 5’CACTTCCTTCTGGAACACTCTCTC3’ 
 
Spliced XBP1 assay 
 cDNA was prepared from 2 µg total kidney RNA as described above, and 
amplification was performed in a Thermocycler using the Taq PCR master mix 
according to manufacturer’s instructions and 0.3 µMol/liter of XBP1 forward and 
reverse primer pairs (table 8). In each cycle, denaturing was at 95°C for 45 s, 
annealing at 55°C for 45 s, extension at 72°C for 4 5 s and a final extension at 
72°C for 4 minutes. A 26 bp fragment containing a P stI restriction site is removed 
following XBP1 mRNA splicing, and PCR products were digested with 20 units 
PstI at 37°C for 1 hour. Digested PCR products were  mixed with a loading dye 
(Qiagen) and were resolved on a 2% agarose gel containing the SYBR safe DNA 
gel stain (Life Technologies, Carlsbad, CA). Microdensitometry plots of 
spliced/unspliced XBP1 bands and housekeeper gene bands were created using 
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ImaegJ software, and the ratio of spliced to unspliced XBP1 was normalized to 
the housekeeper gene.  
Histology 
 Slides were prepared and PAS stains were performed by the Histology 
core in the Department of Pathology and Laboratory Medicine at the Boston 
University School of Medicine. Representative images are shown. 2-4 animals 
were analyzed per group, and 6 images were analyzed per animal.  
 
 
Results 
Renal UPR, ER stress and apoptosis after Stx2 challenge 
 Though there is strong evidence that the UPR, ER stress and downstream 
apoptotic processes take place after Stx challenge in vitro (132), markers of the 
UPR and ER stress have never been assayed in vivo. In order to test the 
hypothesis that Stx2 causes renal transcriptional changes consistent with UPR, 
ER stress and apoptosis, Stx2 challenged animals were euthanized at various 
time points, and kidneys harvested at necropsy were processed for mRNA 
transcriptional analysis as described in materials and methods.   
 Consistent with in vitro observations, kidneys from Stx2 challenged mice 
demonstrated transcriptional changes in markers of the UPR and ER stress 
pathways, though these changes were most pronounced at early time points. 
Spliced XBP1 was up-regulated to 178.7% that of saline on day 2 post challenge 
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and rapidly decreased by euthanasia endpoint (3.3% of saline, p<0.05) (Fig. 
16A). HSP40, a BiP co-factor (140) was significantly elevated at day 2 post Stx2 
challenge (p<0.05) (Fig. 16B), and ER stress marker CHOP was significantly 
elevated on day 3 post-challenge (p<0.05) (Fig. 16C).  
 Transcriptional analysis of anti-apoptotic marker Bcl2 and pro-apoptotic 
marker DR5 at early and late time points yielded interesting results. While the 
renal transcriptional pattern at euthanasia endpoint was consistent with 
apoptosis, with Bcl2 expression down-regulated to 44.37% that of saline controls 
(Fig. 17A) and DR5 expression up-regulated to 419.8% that of saline controls 
(p<0.05)(Fig. 17B), the transcriptional pattern at day 3 post-challenge was 
strongly anti-apoptotic. Anti-apoptotic Bcl2 was up-regulated 370.9% that of 
saline controls, and was significantly elevated compared to kidney Bcl2 
expression at euthanasia endpoint (p<0.001)(Fig. 17A), and pro-apoptotic DR5 
expression was down-regulated 86.7% that of saline controls, and was 
significantly decreased compared to kidney DR5 expression at euthanasia 
endpoint (p<0.01)(Fig. 17B). Taken together, these data are suggestive of Stx2 
induced renal transcriptional changes consistent with the UPR, leading to ER 
stress and ultimately to apoptosis.  
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Figure 16: Stx2 challenged mice demonstrate renal transcriptional patterns 
consistent with UPR and ER stress at early time points. A: Kidney mRNA 
expression of spliced XBP1. n=5 for saline, n=3 for Stx2 (Day 2), n=4 for Stx2 
(Day 3), n=4 for Stx2 (Euthanasia). Significance was determined by Kruskal-
Wallis test with Dunn’s multiple comparison test and is compared to saline unless 
otherwise indicated. *p<0.05, **p<0.01. B: Kidney mRNA expression of HSP40. 
n=5 for saline, n=5 for Stx2 (Day 2), n=10 for Stx2 (Day 3), n=10 for Stx2 
(Euthanasia). Significance was determined by Kruskal-Wallis test with Dunn’s 
multiple comparison test and is compared to saline. *p<0.05. C: Kidney mRNA 
expression of CHOP. n=3 for saline, n=12 for Stx2 (Day 3), n=10 for Stx2 
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(Euthanasia). Significance was determined by Kruskal-Wallis test with Dunn’s 
multiple comparison test and is compared to saline. *p<0.05.  
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Figure 17: Stx2 challenged mice demonstrate anti-apoptotic renal mRNA 
transcriptional patterns at early time points, and pro-apoptotic renal mRNA 
transcriptional patterns at later time points. A: Kidney mRNA expression of 
anti-apoptotic Bcl2. n=5 for saline, n=10 for Stx2 (Day 3), n=10 for Stx2 
(Euthanasia). Significance was determined by Kruskal-Wallis test with Dunn’s 
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multiple comparisons test and is comparing groups as indicated. ***p<0.001. B: 
Kidney mRNA expression of pro-apoptotic DR5. n=5 for saline, n=8 for Stx2 (Day 
3), n=10 for Stx2 (Euthanasia). Significance was determined by Kruskal-Wallis 
test with Dunn’s multiple comparisons test and is compared to saline unless 
otherwise indicated. *p<0.05, **p<0.01.  
 
Renal ER stress and apoptosis after Stx2-producing C. rodentium challenge 
 The Stx2-producing C. rodentium model of Stx2 induced kidney injury 
better replicates the time course of human D+HUS, and also includes intestinally 
located, bacterially produced Stx2. In order to confirm the transcriptional patterns 
consistent with ER stress and apoptosis observed at later time points in the Stx2 
model, kidneys taken at euthanasia from Stx2-producing C. rodentium were 
analyzed for mRNA expression as described in materials and methods.  
 Similar to the data described above, mRNA expression patterns in the 
kidneys of Stx2-producing C. rodentium challenged mice were consistent with ER 
stress and apoptosis. Kidney CHOP expression at euthanasia endpoint in 
C.r(+Stx2) challenged animals was significantly elevated (p<0.001) compared to 
C.r(cntrl) challenged animals, and was 414.1% that of C.r(cntrl) animals (Fig. 
18A). Furthermore, anti-apoptotic Bcl2 was significantly downregulated in 
C.r(+Stx2) challenged animals when compared to C.r(cntrl) animals (p<0.01)(Fig. 
18B), and pro-apoptotic DR5 was significantly upreglated in C.r(+Stx2) 
challenged animals when compared to C.r(cntrl) animals (p<0.001)(Fig. 
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18C).These data demonstrate that renal transcriptional changes consistent with 
ER stress and apoptosis are also occurring in the Stx2-producing C. rodentium 
challenged animals, and the consistency observed in the data sets of the two 
models provides confidence in the validity of the data.  
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Figure 18: Renal transcriptional patterns after murine Stx2-producing C. 
rodentium challenge are consistent with ER stress and apoptosis. A: 
Kidney CHOP expression after Stx2-producing C. rodentium challenge. n=10 
mice per group. Significance was determined using student’s t-test. ***p<0.001. 
B: Kidney expression of anti-apoptotic Bcl2. n=10 mice per group. Significance 
was determined using student’s t-test. **p<0.01. C: Kidney expression of pro-
apoptotic DR5. n=10 mice per group. Significance was determined using 
student’s t-test. ***p<0.001.  
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Murine response to Activated Protein C co-treatment during Stx2 challenge 
 If ER stress and down-stream apoptotic processes are playing major roles 
in Stx2 induced cell death, and thus, in Stx2 induced kidney injury associated 
with lethality, then a reasonable hypothesis is that down-regulation of these 
processes will reverse the transcriptional evidence of these processes, and will 
potentially rescue Stx2 challenged mice. To test this hypothesis, Stx2 challenged 
mice were co-treated with Activated Protein C (APC), which has previously been 
demonstrated to eliminate thapsigargin-induced ER stress in THP1 cells (137), 
and were euthanized on either day 3 or upon reaching euthanasia criteria. At 
euthanasia, kidneys were harvested and processed for analysis of mRNA 
expression as described in materials and methods.  
 Renal mRNA expression of UPR markers spliced XBP1 and HSP40 were 
unchanged on day 3 post-challenge in APC+Stx2 challenged animals (Fig. 19A, 
B; left panels), and though spliced XBP1 was significantly up-regulated at 
euthanasia endpoint in APC+Stx2 challenged animals (p<0.05)(Fig. 19A, right 
panel), HSP40 was unchanged (Fig. 19B, right panel). The up-regulated kidney 
CHOP expression observed in Stx2 challenged animals was significantly 
ameliorated by APC co-treatment (p<0.001) on day 3 post-challenge (Fig. 19C, 
left panel), though no significant changes were observed at euthanasia end-point 
(Fig. 19C, right panel).  
 APC co-treatment’s effects on kidney expression of apoptotic markers was 
contrasting in a manner both dependent on time point and marker analyzed. 
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Whereas anti-apoptotic Bcl2 was significantly elevated (p<0.001) to 615.6% that 
of untreated Stx2 challenged animals at euthanasia endpoint (Fig. 20A, right 
panel) – consistent with APC’s effect on apoptosis down-stream of ER stress – 
kidney Bcl2 expression on day 3 post-challenge was significantly down-regulated 
(p<0.001) to 0.57% that of un-treated Stx2 challenged animals (Fig. 20A, left 
panel). Moreover, not only was pro-apoptotic marker DR5 unchanged at 
euthanasia endpoint (Fig. 20B, right panel), consistent with day 3 renal 
expression of Bcl2, kidney expression of DR5 on day 3 was significantly elevated 
(p<0.001) to 365.4% that of un-treated Stx2 challenged animals (Fig, 20B, left 
panel).  
 Ultimately, APC co-treatment was unable to rescue Stx2 challenged 
animals from lethal kidney injury. Though APC co-treatment was able to extend 
survival time slightly (Stx2: 5.02±1.05 days; APC+Stx2: 5.78±0.44 days)(Fig. 
21A), the effect was significant by only one of the tests used to determine 
significant survival differences (Mantel-Cox test: p=0.17; Gehan-Breslow-
Wilcoxon test: p<0.05), and observed body weight loss was unaltered regardless 
of treatment (Fig. 21B). Stx2 induced plasma BUN was significantly delayed in 
APC+Stx2 challenged animals (p<0.05 on day 3)(Fig. 21C), however mRNA 
expression of kidney injury markers were unchanged at either day 3 or at 
euthanasia endpoint (Fig. 21D-E). Analysis and scoring of kidney samples taken 
on day 3 (data not shown) and at euthanasia endpoint (Fig. 21F) in Stx2 and 
APC+Stx2 challenged animals revealed a similar tubular injury pattern; similar 
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kidney injury was reflected in unaltered histology scores regardless of APC co-
treatment (Fig. 21G).  
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Figure 19: APC co-treatment of Stx2 challenged animals abolishes Stx2 
induced up-regulated kidney expression of ER stress marker CHOP at day 
3. A: Measurement of kidney spliced XBP1 at day 3 (left) or at euthanasia 
endpoint (right). n=3 (day 3) or 4 (euthanasia) for Stx2, n=3 (day 3) or 4 
(euthanasia) for APC+Stx2. Significance was determined by student’s t test. 
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*p<0.05. B: Kidney mRNA expression of HSP40 on day 3 (left) or at euthanasia 
endpoint (right). n=10 for day 3 and euthanasia for Stx2, n=10 (day 3) or 4 
(euthanasia) for APC+Stx2. C: Kidney mRNA expression of CHOP on day 3 (left) 
or at euthanasia endpoint (right). n=12 (day 3) or 10 (euthanasia) for Stx2, n=10 
(day 3) or 4 (euthanasia) for APC+Stx2. Significance was determined by 
student’s t test. ***p<0.001.  
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Figure 20: APC co-treatment of Stx2 challenged animals alters kidney 
mRNA expression of apoptotic markers at early and late time points. A: 
Kidney expression of anti-apoptotic Bcl2 on day 3 (left) or euthanasia endpoint 
(right). n=10 for both day 3 and euthanasia endpoint for Stx2, n=10 (day 3) or 4 
(euthanasia) for APC+Stx2. Significance was determined by student’s t-test. 
***p<0.001. B: Kidney expression of pro-apoptotic DR5 on day 3 (left) or 
euthanasia endpoint (right). n=8 (day 3) or 10 (euthanasia) for Stx2, n=10 (day 3) 
or 4 (euthanasia) for APC+Stx2. Significance was determined by student’s t-test. 
***p<0.001.  
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Figure 21: APC co-treatment of Stx2 challenged mice did not rescue mivr 
from kidney injury associated with lethality . A: Survival of Stx2 and 
APC+Stx2 challenged mice. n=44 for Stx2, n=10 for APC+Stx2. Significance was 
determined by Mantel-Cox test (p=0.17) and Gehan-Breslow-Wilcoxon test 
(p<0.05). B: Percent total body weight of Stx2 and APC+Stx2 challenged mice. 
Mean and standard deviation are shown. n=26 for Stx2, n=19 for APC+Stx2. C: 
Plasma BUN of Stx2 and APC+Stx2 challenged mice. Mean and standard 
deviation are shown. n=22 for Stx2, n=14 for APC+Stx2. Significance was 
determined by repeated measures ANOVA with Bonferroni post-test. *p<0.05. D: 
Kidney mRNA expression of kidney injury marker NGAL on day 3 (left) or 
euthanasia (right). n=12 (day 3) or 5 (euthanasia) for Stx2, n=5 (day 3) or 4 
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(euthanasia) for APC+Stx2. E: Kidney mRNA expression of kidney injury marker 
KIM1 on day 3 (left) or euthanasia (right). n=12 (day 3) or 5 (euthanasia) for Stx2, 
n=10 (day 3) or 4 (euthanasia) for APC+Stx2. F: Representative PAS stained 
images of kidneys from Stx2 or APC+Stx2 challenged mice. Magnification and 
time of euthanasia is as noted in figure. G: Quantification of kidney injury on day 
3 (left) or euthanasia (right). n=2 (day 3) or 4 (euthanasia) for Stx2, n=2 for 
APC+Stx2 at both time points. Six images were scored per animal, and images 
were blinded before analysis.  
 
Murine response to APC+C.r(+Stx2) challenge 
 In order to confirm the data described above – that though APC co-
treatment of Stx2 challenged animals alters transcriptional patterns consistent 
with ER stress and apoptosis, it does not rescue mice from lethal kidney injury – 
C.r(+Stx2) challenged animals were also co-treated with APC as described in 
materials and methods. We hypothesized that APC co-treatment of mice 
challenged with Shiga toxin producing C. rodentium would yield changes in the 
ER stress and apoptosis consistent renal transcriptional pattern, while not 
altering markers of lethal kidney injury.  
 mRNA expression patterns in kidneys of APC co-treated mice challenged 
with Shiga toxin producing C. rodentium were consistent with down-regulation of 
ER stress and the intrinsic pathway of apoptosis. Renal CHOP expression in 
APC co-treated animals was significantly down-regulated to 34.29% that of un-
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treated animals (p<0.05)(Fig. 22A), and renal anti-apoptotic Bcl2 expression in 
APC co-treated animals was significantly up-regulated to 423.9% that of un-
treated animals (p<0.001)(Fig. 22B). Consistent with observations in APC+Stx2 
challenged mice, kidney expression of pro-apoptotic DR5 was unchanged in APC 
co-treated Stx2-producing C. rodentium challenged animals (Fig. 22C).  
 Also consistent with observations in APC+Stx2 challenged animals were 
APC’s effects on lethal kidney injury in Stx2-producing C. rodentium challenged 
animals. A slight, though non-significant, survival benefit was observed in APC 
co-treated animals (Mean survival time – C.r(+Stx2): 7.8±0.77 days; 
APC+C.r(+Stx2): 8.3±1.53 days)(Fig. 23A) and early changes to body weight 
loss were observed (Fig. 23B). APC co-treatment of C.r(+Stx2) challenged 
animals also had early effects on colonization and plasma BUN. Colonization 
was significantly lower at early time points in APC+C.r(+Stx2) challenged animals 
as compared to untreated C.r(+Stx2) challenged animals (p<0.001 on day 2; 
p<0.01 on day 3)(Fig. 23C), and plasma BUN was significantly lower in 
APC+C.r(+Stx2) challenged animals as compared to untreated C.r(+Stx2) 
challenged animals on day 3 (p<0.05) and day 7 (p<0.05). Kidney mRNA 
expression of kidney injury markers NGAL and KIM1 were unchanged in 
APC+C.r(+Stx2) challenged animals (Figs. 23E-F).  
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Figure 22: APC co-treatment of C.r(+Stx2) challenged animals alters kidney 
mRNA expression of CHOP and anti-apoptotic Bcl2, but not pro-apoptotic 
DR5. A: Kidney mRNA expression of ER stress marker CHOP. n=10 for 
C.r(+Stx2), n=3 for APC+C.r(+Stx2). Significance was determined by student’s t 
test. *p<0.05. B: Kidney mRNA expression of anti-apoptotic Bcl2. n=10 for 
C.r(+Stx2), n=3 for APC+C.r(+Stx2). Significance was determined by student’s t 
test. ***p<0.001. C: Kidney mRNA expression of pro-apoptotic DR5. n=9 for 
C.r(+Stx2), n=3 for APC+C.r(+Stx2).  
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Figure 23: APC co-treatment of Stx2-producing C. rodentium challenged 
animals did not rescue mice from lethal kidney injury. A: Survival of 
challenged animals. n=19 for C.r(+Stx2), n=10 for C.r(cntrl), n=3 for 
APC+C.r(+Stx2). B: Percent total body weight loss of challenged animals. Body 
weight was set at 100% on day 0, mean and standard deviation are shown. n=19 
for C.r(+Stx2), n=10 for C.r(cntrl), n=3 for APC+C.r(+Stx2). C: Colonization in 
challenged animals. Mean and standard deviation are shown. n=19 for 
C.r(+Stx2), n=10 for C.r(cntrl), n=3 for APC+C.r(+Stx2). Significance was 
determined by repeated measure ANOVA with Bonferroni post-test. **p<0.01, 
***p<0.001.  D: Plasma BUN of challenged animals. Mean and standard 
deviation are shown. n=19 for C.r(+Stx2), n=10 for C.r(cntrl), n=3 for 
APC+C.r(+Stx2). Significance was determined by repeated measure ANOVA 
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with Bonferroni post-test. *p<0.05 E, F: Kidney mRNA expression of kidney injury 
markers NGAL (E) and KIM1 (F). n=10 for C.r (+Stx2), n=3 for APC+C.r(+Stx2).  
 
Murine response to Nilotinib co-treatment during Stx2 challenge 
 The observation that APC co-treatment did not rescue Stx2 induced lethal 
kidney injury and did not alter Stx2 induced renal up-regulation of DR5 led us to 
hypothesize that kidney apoptotic signaling was still occurring in APC co-treated 
challenged animals. Apoptotic signaling is a downstream effect of the ribosomal 
stress response (133), and inhibition of the MAP3K ZAK, a molecule 
hypothesized to transduce the signal from the Stx2- damaged ribosome to the 
SAPK JNK, is beneficial in vitro (136).To test the hypothesis that RSR signaling 
was contributing to Stx2 induced renal apoptosis and lethal kidney injury in Stx2 
challenged animals, mice were co-treated with the ZAK inhibitor Nilotinib (138) as 
described in materials and methods. If the RSR is contributing to Stx2 induced 
renal DR5 up-regulation in Stx2 challenged animals, then Nilotinib co-treatment 
should ameliorate the observed Stx2 induced renal DR5 up-regulation.  
 Nilotinib co-treatment of Stx2 challenged animals did not alter survival or 
body weight loss (Figs. 24 A-B), nor were markers of kidney injury down-
regulated (Figs. 24 C-E). Since Nilotinib co-treated animals did not receive APC, 
and the ER stress marker CHOP was not altered in these animals (data not 
shown), it was not surprising that lethal kidney injury was still occurring. 
However, contrary to our hypothesis, renal expression of anti-apoptotic Bcl2 (Fig. 
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24F) and pro-apoptotic DR5 (Fig. 24G) were unaltered by Nilotinib co-treatment. 
These data are not supportive for a benefit to down-regulation of the RSR 
through Nilotinib co-treatment, and do not support the hypothesis that Stx2 
mediated RSR is contributing to continued apoptotic signaling during APC co-
treatment of Stx2 challenged animals.  
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Figure 24: Nilotinib co-treatment of Stx2 challenged animals does not 
rescue mice from lethal kidney injury and does not alter Stx2 induced 
kidney expression of Bcl2 and DR5. A: Survival of challenged animals. n=44 
for Stx2, n=10 for saline, n=5 for Nilotinib+Stx2. B: Percent total body weight loss 
of challenged animals. Body weight was set at 100% on day 0, and mean and 
standard deviations are shown. n=26 for Stx2, n=10 for saline, n=5 for 
Nilotinib+Stx2. Significance was determined by repeated measures ANOVA with 
Bonferroni post-test. *p<0.05. C: Plasma BUN of challenged animals. n=35 for 
Stx2, n=10 for saline, n=5 for Nilotinib+Stx2. D, E: Kidney mRNA expression of 
kidney injury markers NGAL (D) and KIM 1(E). n=5 for Stx2, n=3 for 
0 2 4 6 8
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Nilotinib+Stx2. F: Kidney mRNA expression of anti-apoptotic Bcl2. n=10 for Stx2, 
n=3 for Nilotinib+Stx2. G: Kidney mRNA expression of pro-apoptotic DR5. n=10 
for Stx2, n=3 for Nilotinib+Stx2.  
 
Murine response to Z-VAD-FMK+Stx2 and Z-VAD-FMK+APC+Stx2 challenge 
 That down-regulation of the RSR through Nilotinib co-treatment of Stx2 
challenged animals did not reverse Stx2 induced renal DR5 up-regulation did not 
dispute the previously described hypothesis: that continued renal DR5 up-
regulation is causing continued apoptotic signaling even during APC co-
treatment induced anti-apoptotic Bcl2 up-regulation. Over-expression of DR5, a 
member of the TNFR family, can signal apoptosis in a ligand independent 
manner (141), and it has been demonstrated that activation of another pro-
apoptotic member of the TNFR family, Fas, can induce apoptosis even when 
anti-apoptotic Bcl2 expression is up-regulated (142). To determine if pro-
apoptotic DR5 is playing a role in the lethal kidney injury observed in APC co-
treated Stx2 challenged animals, Stx2 challenged animals were co-treated with 
the pan-caspase inhibitor Z-VAD-FMK (ZVAD)(139), with or without APC co-
treatment.  
 ZVAD co-treatment of Stx2 challenged animals did not demonstrate a 
survival benefit, as the average survival time was 4.75±1.1 days (Fig. 25A, left). 
Moreover, ZVAD co-treatment ameliorated APC’s modest survival benefit, 
shortening the average survival time from 5.78±0.44 days in APC co-treated Stx2 
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challenged animals to 5±0.44 days in ZVAD and APC co-treated Stx2 challenged 
animals (Fig. 25A, right). Observed total body weight loss was unchanged in 
ZVAD co-treated or ZVAD and APC co-treated animals (Fig. 25B), nor were any 
alterations in plasma BUN observed (Fig. 25C). Though kidney mRNA 
expression of the kidney injury marker NGAL was unaltered by ZVAD or ZVAD 
and APC co-treatment at any time point analyzed (Fig. 25D), kidney expression 
of injury marker KIM1 was significantly lower in ZVAD co-treated animals 
compared to untreated animals on day 3 (Fig. 25E, left), and compared to APC 
co-treated animals at euthanasia endpoint (Fig. 25E, right). However, as no 
alterations in the other kidney injury markers – plasma BUN and kidney 
expression of NGAL – were observed in ZVAD co-treated or ZVAD and APC co-
treated animals, the relevance of this finding is difficult to interpret. These data 
are not supportive of a role for pro-apoptotic caspases in Stx2 mediated murine 
lethal kidney injury.  
 Renal mRNA expression of UPR marker HSP40 and ER stress marker 
CHOP were also unaltered by either ZVAD or ZVAD and APC co-treatment at 
any time point analyzed (Figs. 26A-B). Similar to ZVAD’s effects on survival time 
in APC co-treated animals, APC induced up-regulation of kidney Bcl2 expression 
was significantly ameliorated (p<0.01) in ZVAD and APC co-treated animals (Fig. 
26C, right). Kidney Bcl2 expression was also significantly down-regulated in 
ZVAD co-treated animals at day 3 (p<0.001)(Fig. 26C, left), and no differences in 
kidney expression of pro-apoptotic DR5 were observed at any time point (Fig. 
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26D). Taken together, these data suggest that inhibition of caspases during Stx2 
challenge causes kidney mRNA patterns consistent with apoptosis earlier then 
observed in un-treated animals, and furthermore, abolishes survival and anti-
apoptotic benefits of APC co-treatment.  
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Figure 25: ZVAD co-treatment of APC co-treated Stx2 challenged animals is 
not beneficial. A: Survival of Stx2, ZVAD+Stx2 (left), APC+Stx2 and 
ZVAD+APC+Stx2 (right) challenged animals. n=44 for Stx2, n=4 for ZVAD+Stx2, 
n=9 for APC+Stx2, n=8 for ZVAD+APC+Stx2. B: Percent total body weight loss 
of Stx2, ZVAD+Stx2 (left), APC+Stx2 and ZVAD+APC+Stx2 (right) challenged 
animals. Body weight on day 0 was set at 100%; mean and standard deviations 
are shown.  n=26 for Stx2, n=9 for ZVAD+Stx2, n=19 for APC+Stx2, n=8 for 
ZVAD+APC+Stx2. C: Plasma BUN levels of Stx2, ZVAD+Stx2 (left), APC+Stx2 
and ZVAD+APC+Stx2 (right) challenged animals. Mean and standard deviations 
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are shown. n=35 for Stx2, n=9 for ZVAD+Stx2, n=14 for APC+Stx2, n=8 for 
ZVAD+APC+Stx2. D: Kidney mRNA expression of injury marker NGAL in 
challenged animals at day 3 (left) or euthanasia (right). n=12 (day 3) or 5 
(euthanasia) for Stx2, n=5 (day 3) or 4 (euthanasia) for ZVAD+Stx2, n=4 for 
APC+Stx2, n=4 for ZVAD+APC+Stx2. E: Kidney mRNA expression of injury 
marker KIM1 in challenged animals at day 3 (left) or euthanasia (right). n=12 (day 
3) or 5 (euthanasia) for Stx2, n=5 (day 3) or 4 (euthanasia) for ZVAD+Stx2, n=4 
for APC+Stx2, n=4 for ZVAD+APC+Stx2. Significance was determined by 
student’s t-test (left) or Kruskal-Wallis test with Dunn’s repeated measures test 
(right). *p<0.05.  
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Figure 26: ZVAD co-treatment of APC co-treated Stx2 challenged animals 
does not alter renal UPR or ER stress, and down-regulates Bcl2. A: Renal 
expression of HSP40 on day 3 (left) and at euthanasia (right). n=10 for Stx2, n=5 
(day 3) or 4 (euthanasia) for ZVAD+Stx2, n=4 for APC+Stx2 and 
ZVAD+APC+Stx2. B: Renal expression of CHOP on day 3 (left) and at 
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euthanasia (right). n=12 (day 3) or 10 (euthanasia) for Stx2, n=5 (day 3) or 4 
(euthanasia) for ZVAD+Stx2, n=4 for APC+Stx2 and ZVAD+APC+Stx2. C: Renal 
expression of pro-apoptotic Bcl2 on day 3 (left) or euthanasia (right). n=10 for 
Stx2, n=5 (day 3) or 4 (euthanasia) for ZVAD+Stx2, n=4 for APC+Stx2 and 
ZVAD+APC+Stx2. Significance was determined by student’s t-test (left) or 
Kruskal-Wallis test with Dunn’s multiple comparisons test. **p<0.01, ***p<0.001. 
D: Renal expression of anti-apoptotic DR5 on day 3 (left) or euthanasia (right). 
n=8 (day 3) or 10 (euthanasia) for Stx2, n=5 (day 3) or 4 (euthanasia) for 
ZVAD+Stx2, n=4 for APC+Stx2 and ZVAD+APC+Stx2.  
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Summary and discussion 
 The studies presented in this chapter show that Stx2 induced lethal kidney 
injury in vivo is accompanied by transcriptional changes in UPR, ER stress and 
apoptotic markers. These data are consistent with in vitro studies. Lee et al 
showed that Stx1 challenge of THP-1 cells results in caspase-8 activation, 
leading to processes consistent with the formation of the apoptosome (127), and 
ultimately identified the mechanism response for the observed apoptosis as 
being the UPR and ER stress response (132), as evidenced by increased spliced 
XBP1 mRNA, and increased mRNA and protein expression of ER stress marker 
CHOP in Stx1 challenged THP1 cells. Decreased mRNA and protein expression 
of anti-apoptotic Bcl2 and increased mRNA and surface protein expression of 
pro-apoptotic DR5 were also observed. Our work confirms that many of the UPR 
and ER stress markers identified as up-regulated following in vitro Stx1 challenge 
are similarly up-regulated in in vivo models of Stx2 induced kidney injury, 
including increased XBP1 splicing and up-regulated CHOP. Such transcriptional 
alterations were observed in two models of Stx2- toxemia. 
 An unexpected finding of this study was the characterization of the timing 
of transcriptional alterations in anti-apoptotic Bcl2 and pro-apoptotic DR5. We 
observed that kidney mRNA expression of anti-apoptotic Bcl2 and pro-apoptotic 
DR5 were down-regulated and up-regulated, respectively, at euthanasia; these 
observations are consistent with DNA fragmentation following Stx1 or Stx2 
challenge of human renal cortical epithelial cells (128), and TUNEL positive cells 
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in renal cortices of EHEC infected mice and children with HUS (30). The finding 
that the renal transcriptional pattern is strongly anti-apoptotic on day 3 post-
challenge is novel, however, and supports an anti-apoptotic function for the renal 
ER stress response in early Stx2 induced kidney pathogenesis. This hypothesis 
is further supported by the finding that APC co-treatment resulted in opposite 
expression patterns of anti-apoptotic Bcl2 and pro-apoptotic DR5 on day 3.  
 In order to address whether Stx2 induced ER stress and apoptosis is a 
driving mechanism in kidney cell death, leading ultimately to kidney organ injury, 
we utilized Activated Protein C (APC), an anti-coagulant with described 
cytoprotective effects (reviewed in (143)), that has been shown to down-regulate 
thapsigargin- induced ER stress processes in vitro (137). APC is the activated 
version of the vitamin K-dependent serine protease zymogen Protein C, and 
once activated by the thrombin-thrombomodulin complex, APC demonstrates 
anticoagulant activity by degrading cofactors Va and VIIIa (144-146). It has been 
hypothesized that APC’s cytoprotective effects are mediated by its interaction 
with the endothelial protein C receptor (EPCR) and the binding of APC-EPCR to 
protease- activated receptor 1 (PAR-1) (143, 147).That the molecular features 
dictating APC’s anticoagulant effects are distinct from those dictating APC’s 
cytoprotective effects (148, 149) indicates that a recombinant form of APC could 
potentially be used therapeutically to down-regulate ER stress and apoptotic cell 
responses without altering haemostasis. APC has been shown to be effective in 
the inhibition of glomerular apoptosis in a murine model of diabetic nephropathy 
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(150), and a recombinant APC variant with reduced anticoagulant activity was 
demonstrated to reduce murine morality after LPS challenge (151). 
 Consistent with described in vitro studies, animals co-treated with APC 
showed significantly decreased kidney mRNA expression of CHOP, as well as 
significantly increased expression of anti-apoptotic Bcl2. Such effects of APC 
were observed in both models of Stx2- toxemia. These data extend the work of 
Toltl et al and shows that APC can down-regulate ER stress in vivo. However, 
despite transcriptional evidence of down-regulation of the ER stress pathway, 
APC co-treatment did not alter renal expression of DR5, and was not able to 
prevent mortality in either model. These data led us to hypothesize that, despite 
the renal Bcl2 up-regulation observed in APC co-treated animals, the unchanged 
kidney DR5 expression is allowing for apoptotic signaling to occur in these 
animals.  
Consistent with this hypothesis is the work of Huang et al, who 
demonstrated that up-regulation of anti-apoptotic Bcl2 and the related anti-
apoptotic Bcl-xL is unable to rescue murine primary cells from apoptotic signaling 
mediated by the DR5- related pro-apoptotic Fas (142). That Nilotinib co-
treatment failed to alter renal DR5 expression was not consistent with the 
hypothesis that the RSR was driving the continued renal DR5 expression in APC 
co-treated animals.  Co-treatment of Stx2 challenged mice with the pan-caspase 
inhibitor ZVAD either alone, or in conjunction with APC, was not only unable to 
recue animals from lethal kidney injury, but also ameliorated APC’s alterations of 
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kidney transcriptional patterns and modest survival benefit. It is important to note, 
however, that vehicle-treated controls were not run in parallel during any of the 
above described experiments. This complicates interpretation of the data.  
Though these data are not supportive of a major role for ER stress 
induced apoptotsis in Stx2 induced kidney cell death and kidney organ injury, 
when taken with observations made by others, they provide insight into the 
intracellular Stx2 signaling that mediates Stx2- induced cell death. Such 
observations include those by Nishikawa et al (152) and Stearns-Kurosawa et al 
(153), who demonstrate that EHEC challenged mice  and Stx2 challenged non-
human primates can be rescued by administration of a therapeutic tetravalent 
peptide (TVP). The mechanism of rescue was identified by Nishikawa et al as 
being related to the intracellular trafficking of Stx2. Stx2 still bound to its receptor 
and underwent retrograde transport to the Golgi apparatus in the presence of 
TVP, but did not undergo further retrograde transport to the ER. Rather, in the 
presence of TVP, Stx2 was degraded in the acidic compartment (152).  
It has been hypothesized that Shiga toxin interaction with ER chaperone 
proteins allows for Stx translocation from the ER to the cytoplasm (154, 155), and 
further highlighting the importance of trafficking to the ER in Stx cytotoxicity is the 
work of Smith et al, who described a requirement for adequate glucosylceramide 
cellular levels for appropriate Stx1 trafficking (156). Under low glucosylceramide 
conditions, though Stx still binds its receptor and is trafficked to the ER, it is no 
longer able to translocate across the ER membrane, and cytotoxicity is 
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abolished. Taken together, these data, in conjunction with observations made in 
APC co-treated Stx2 challenged mice, support the hypothesis that though down-
regulation of Stx2 induced ER-stress responses is unable to prevent cytotoxicity, 
Stx2 trafficking to the ER is an essential step in Stx2 mediated cell death.  
 
CHAPTER FIVE: DISCUSSION AND FUTURE DIRECTIONS 
 
Treatment for HUS - the potentially lethal complication of EHEC infection 
that is a leading cause of kidney failure in otherwise healthy children – is 
currently limited to supportive care (9, 64), as no toxin or pathogen specific 
treatment exists. The studies presented herein were designed to identify and 
characterize two potential therapeutic targets in human D+HUS: host immune-
responses, and kidney cell stress responses. Examination of either topic required 
a cost-effective, easily manipulated animal model, and two mouse models of 
Stx2-induced lethal kidney injury, as well as the markers that reported on organ 
injury and disease severity, were therefore described. Use of the two murine 
models allowed for thorough description of mouse kidney pathology elicited by 
Stx2, and what roles host immune and kidney cell stress responses were playing 
in this process were also examined. In this chapter, we briefly summarize the 
findings of this study, as well as the limitations of the study and the future 
directions we believe the study has inspired.  
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Experimental Design and Scientific Rigor 
Insufficient experimental reporting on the design, conduct and analysis of 
published experiments has been the topic of several recent articles (157). Such 
deficiencies in experimental reporting makes these published studies difficult to 
reproduce, which in turn, makes interpretation complex. Upholding certain core 
standards - such as those described by Landis et al (157), an adapted version of 
which was proposed by the NIH as a universal checklist to be used during 
editorial processing – is a crucial part of the scientific process, as advances in 
disease treatments rely on the dependability of published observations. These 
core standards include the following: randomization, blinding, sample-size 
estimation, and appropriate data handling.   
With regard to the above studies, important limitations were introduced by 
not statistically determining the number of animals allocated to each group, and 
by comparing the same untreated control group to multiple different treatment 
groups, rather than utilizing appropriate isotype antibody or vehicle controls in 
treated animal experiments. These issues will be rectified in future work. It is 
especially important that such scientific standards be followed during 
translational research, as failure to do so results in observations that cannot be 
reproduced, which hinders the scientific process, and thus, the development of 
potential therapeutics.   
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Animal models 
 To date, the only animal model to fully replicate the complete disease 
spectrum of HUS is the non-human primate HUS model (70-72, 153, 158). 
Baboons (Papio) challenged with LPS-free Stx1 (100 ng/kg) or Stx2 (50 ng/kg) 
demonstrate thrombocytopenia, anemia and acute renal failure, in a dose-
dependent fashion (158). This makes it invaluable as a preclinical model with 
which to test potential therapeutics; however, the cost of this model makes it 
impractical for mechanistic studies.  
 In order to identify and characterize mechanisms of host immune-
responses and kidney cell stress responses in in vivo Stx2 induced kidney injury, 
low-cost mouse models were developed and introduced to the Kurosawa lab. 
The Stx2 challenge model utilized two I.P. injections of LPS-free Stx2 (0.05 ng/g, 
days 0 and 3), and the Stx2-producing C. rodentium model (88) employed a 
single oral gavage of 1E9 CFU. In both models, periodic phlebotomy was 
performed to assay the kidney injury marker plasma BUN, and animals 
euthanized upon losing >20% total body weight underwent necropsy and organ 
harvest. Organs were processed for either qPCR analysis of kidney injury 
markers NGAL (89) and KIM1 (90) or histological analysis of kidney pathology.  
 Mice in both models presented with kidney injury associated lethality, as 
demonstrated by increasing plasma BUN with time, increased kidney mRNA 
expression of NGAL and KIM1, and kidney pathology exhibiting a focal, tubular 
pattern of injury. The timing of kidney injury development in both mouse models 
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was more rapid than the clinically observed time course, and the pattern of 
kidney injury observed histologically in both models was also distinct from what is 
observed clinically. Whereas observed kidney pathology in D+HUS patients 
includes glomerular thrombosis and congestion and endothelial swelling (31, 32), 
kidney pathology in the mouse models was limited to a focal, tubular injury 
pattern, and no glomerular pathology was observed. Differences in kidney 
pathology between D+HUS patients and the mouse models are likely attributable 
to differences in renal expression of the Stx receptor Gb3. In humans, Gb3 is 
renally expressed on both the glomerular endothelium and tubular epithelium (29, 
30). In mice, renal expression of Gb3 is limited to the tubular epithelium (76). 
 Differences in Gb3 expression may also explain the major limitation of the 
utilized mouse models: neither model demonstrates the thrombocytopenia and 
hemolytic anemia (data not shown) which are partially defining of HUS (18-20). 
Unless co-challenged with an additional pro-inflammatory mediator such as LPS 
(91, 92), no mouse model, or any small animal model, presents with full-
spectrum HUS (70), and the relevance of LPS co-challenge to clinical disease 
pathogenesis is unclear, as the coagulation profile observed in these animals is 
that of a DIC (93, 94). EHEC challenged gnotobiotic piglets demonstrate renal 
thrombotic microangiopathy, however neither thrombocytopenia nor schistocytes 
in peripheral blood smears are observed (159); EHEC challenged Dutch belted 
rabbits present with glomerular injury and glomerular thrombi, however mild to 
moderate thrombocytopenia was observed in only a subset of challenged 
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animals, and no changes in creatinine were described (160). A murine model that 
presents with full spectrum HUS – thrombocytopenia, hemolytic anemia, 
thrombotic microangiopathy and kidney injury – would greatly benefit the field, in 
that it would allow not only for examination of mechanisms mediating Stx2 
induced kidney injury, but Stx2 induced endothelial injury as well. If the lack of 
observed full spectrum HUS in the previously described mouse models is driven 
by the murine Gb3 expression pattern, then a reasonable hypothesis is that 
altering murine Gb3 expression so that it is expressed on the renal endothelium, 
as well as the epithelium, may result in a mouse model with full spectrum HUS.  
 A mouse model initially developed to study Fabry disease, a human X-
linked recessive disorder characterized by deficiency in the lysosomal enzyme α-
galactosidase A (α-GalA) (161, 162), appears to meet these criteria. α-GalA 
deficient individuals demonstrate excessive Gb3 in multiple tissues, and similarly, 
Gb3 expression, as measured by a StxB binding assay, is 100- fold higher in the 
kidneys of α-GalA-knockout (α-GalA-KO) mice than in wild-type mice (163). 
Increased Gb3 expression was noted in other organs as well, including spleen, 
liver and heart. Cilmi et al hypothesized that the increased Gb3 in these mice 
would lead to increased Stx2 susceptibility, however, the α-GalA-KO phenotype 
was found to be protective against both Stx2 and EHEC challenge (164). Co-
treatment of α-GalA-KO mice with recombinant α-GalA restored the susceptibility 
of α-GalA-KO mice to lethal Stx2, suggesting that the excess Gb3 in these mice 
acted as a toxin sink (164).  
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 If murine over-expression of Gb3 by general α-GalA knockout ameliorates 
toxin ability to reach Stx2-specific organs, then perhaps  a conditional α-GalA 
knockout, such that the molecule is only absent in endothelial cells, will result in a 
mouse model presenting with full spectrum HUS. A Tek-Cre mouse, in which Cre 
recombinase is expressed under the direction of the endothelial cell specific 
(165) receptor tyrosine kinase Tek promoter, is commercially available (Jackson 
Laboratory, B6.Cg-Tg(Tak-Cre)12Flv/J). When crossed with a transgenic mouse 
in which the α-GalA gene is surrounded by loxP sites oriented in the same 
direction, the resulting offspring will theoretically have over-expression of Gb3 in 
only endothelial cells. If endothelially expressed Gb3 is required for a mouse 
model of full spectrum HUS, then Stx2 challenge of this resulting offspring will 
result in thrombocytopenia, hemolytic anemia, and kidney failure with both 
glomerular and tubular injury; challenge of such a mouse with Stx2-producing C. 
rodentium should yield a mouse model with full spectrum D+HUS – an intestinal 
infection with an A/E lesion producing, Stx2 secreting bacterium, that presents 
with thrombocytopenia, hemolytic anemia, and kidney failure with glomerular and 
tubular injury, and histological evidence of glomerular thrombotic 
microangiopathy.  
Host-immune responses 
A general role for host-immune responses in D+HUS pathogenesis is 
supported by clinical observations (31, 32, 95, 96) and animal models (72, 77). 
Leukocytes are hypothesized to play a more specific role in systemic toxin 
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trafficking, supported by observed Stx antigen on the surface of circulating 
neutrophils form a subset of D+HUS patients (113, 114). Little experimental 
testing for either a general role for host-immune responses in D+HUS or a 
specific leukocyte role in systemic toxin trafficking has been done in vivo, 
however, and if found to be true, no therapeutic opportunities have been tested. 
A series of experiments were therefore designed to test the hypothesis that, if 
host-immune responses are playing roles in either murine Stx2-induced lethal 
kidney injury or murine systemic Stx2 trafficking, then down-regulation of such 
host-immune responses will lead to therapeutic benefit.  
Kidneys from Stx2 challenged animals euthanized on day 3 were 
processed for either qPCR analysis of chemokines KC and mip-2α, or flow 
cytometry analysis of kidney neutrophils. Down-regulation of host-immunity was 
achieved through co-treatment with either the mustard alkylating agent 
cyclophosphamide or the anti-Ly6G/anti-Ly6C monoclonal antibody GR1; Stx2 or 
Stx2-producing C. rodentium challenged animals were co-treated with 2 mg 
cyclophosphamide (Stx2 [days 0 and 3] and C.r(+Stx2) [days 0-3] challenges) or 
250 µg GR1 (C.r(+Stx2) challenge, days 0-3). Survival time in co-treated animals 
was observed, and markers of kidney injury, including plasma BUN, and kidney 
mRNA expression of NGAL and KIM1, were assayed.  
Consistent with a role for host-immunity in Stx2-induced kidney injury, 
increased renal mRNA expression of chemokines KC and MIP-2α, as well as 
increased kidney neutrophils, were observed following murine Stx2 challenge. 
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Rendering Stx2 challenged mice leukopenic with cyclophosphamide, however, 
did not rescue animals from lethal kidney injury, and similar results were obtained 
when Stx2-producing C. rodentium challenged mice were co-treated with GR1. In 
both cases, mortality rates and kidney injury markers were unchanged in 
leukopenic animals compared to non-leuokpenic animals, suggesting that host-
immunity is not playing a major role in Stx2- induced murine kidney injury. Stx2 
toxoid binding to mouse neutrophils and lymphocytes, and Stx2 binding to mouse 
bone marrow cells, was not detectable by flow cytometry, and Stx2 was found to 
interact with only the plasma fraction of human blood following a 30 minute 
incubation. Neither result is consistent with a major role for leukocytes in 
systemic toxin trafficking.  
An unexpected role for host-immunity in colonization control of Stx2-
producing C. rodentium was identified when mice were co-treated with 
cyclophosphamide during Stx2-producing C. rodentium challenge. Colonization 
levels in these mice were over 5-log-fold higher than those observed in 
cyclophosphamide co-treated non-Stx2-producing C. rodentium challenged 
animals, suggesting that the presence of intestinal Stx2 was necessary for the 
observed colonization increases. Amelioration of these colonization increases by 
co-treatment with the humanized anti-Stx2 antibody further supported this 
hypothesis.  
Both hematopoietic cells and intestinal epithelial cells are susceptible to 
cyclophosphamide (121) . Co-treatment with the more specific leucopenia 
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inducing agent GR1 did not phenocopy observed colonization increases in 
cyclophosphamide co-treated animals, suggesting that GR1 is not affecting an 
aspect of host-immunity that the more broadly acting cyclophosphamide is 
affecting. When taken in conjunction with the observation that passive immunity 
with an anti-Stx2 antibody abolishes the observed colonization increases, these 
data suggest that the aspect of host-immunity which is controlling C.r(+Stx2) 
colonization in the absence of cyclophosphamide must be sensitive to both 
cyclophosphamide and Stx2.  
Stx binding sites in the mouse colon are limited to the distal colon, 
particularly the crypts of Lieberkühn – which, in the small intestine, contain anti-
microbicidal secreting Paneth cells (166-168) – and Gb3 expression in the 
intestine of humans is confined to Paneth cells, pericryptal myofibroblasts and 
endothelial cells in the lamina propria (110). Thus, a possible hypothesis is that 
the increased Stx2-producing C. rodentium colonization observed in 
cyclophosphamide co-treated animals is mediated by decreased microbicidal α-
defensin secretion by CP/Stx2-altered Paneth cells. This hypothesis is supported 
by the observations of Islam et al, who found that mRNA levels of the human 
antibacterial peptide LL-37 (169, 170) were decreased in gut biopsies from 
patients infected with the Shiga toxin producing Shigella dysenteriae when 
compared to control biopsies; this finding was confirmed in vitro, and S. 
dysenteriae infection of the epithelial cell line HT-29 led to LL-37 mRNA down-
regulation (171). 
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Interestingly, no obvious intestinal damage was observed in any C. 
rodentium challenged mice (data not shown, unpublished observations of M.J. 
O’Brien, M.D., M.P.H.), indicating that if CP/Stx2-Paneth cell interactions are 
mediating the observed colonization increases, the interaction is not eliciting 
gross histological changes in the small or large intestine of mice. An alternative 
hypothesis is that CP/Stx2 are interacting with other aspects of intestinal 
immunity, such as colonization resistance. Cyclophosphamide treatment has 
been demonstrated previously to alter the intestinal balance of protective and 
pathogenic bacteria in mice (172), and in further support of this hypothesis is the 
work of Calderon Toledo et al, who demonstrated that MyD88 knockout mice are 
particularly sensitive to Stx2-producing EHEC infection (173). No differences in 
susceptibility of MyD88 knockout mice to non-Stx2-producing EHEC strains were 
observed. Notably, MyD88 knockout mice are also deficient in the intestinal 
lumen bactericidal lectin RegIII gamma, which has been shown to enhance 
infection clearance in wild-type mice (174); both decreases in host-immunity and 
bactericidal molecule expression within the intestine may therefore be 
contributing to the increased susceptibility to Stx2-producing bacteria observed in 
the MyD88 knockout mice and the cyclophosphamide co-treated mice.  
Different approaches can be taken in designing subsequent experiments 
to characterize the roles that host-immunity and microbicidal peptides play in 
Stx2-producing C. rodentium colonization control. One approach is to 
measurement of α-defensin levels in the intestines of mice infected with Stx2-
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producing or non-Stx2-producing C. rodentium, with or without 
cyclophosphamide co-treatment. If α-defensin levels are mediating C. rodentium 
colonization control, then α-defensin mRNA expression levels should be highest 
in non-Stx2-producing C. rodentium infected mice, lower in Stx2-producing C. 
rodentium infected mice, and lowest in cyclophosphamide co-treated Stx2-
producing C. rodentium infected mice. An alternative approach is to assay 
colonization levels following Stx2-producing C. rodentium infection of mice 
lacking α-defensins. α-defensin precursors require cleavage by MMP7 for 
bactericidal activity (175), and an MMP7 knockout mouse that lacks mature crypt 
defensin proteins in intestinal epithelium is commercially available (Jackson 
laboratory, B6.129-Mmp7tm1Lmm/J; Jackson laboratory data sheet). If α-defensins 
are mediating control of Stx2-producing C. rodentium infection, then MMP7 
knockout mice should demonstrate increased colonization similar to what is 
observed in cyclophosphamide co-treated Stx2-producing C. rodentium 
challenged mice.  
 
Kidney cell stress responses 
 
 In vitro data are supportive of a role for cell stress pathways, such as the 
ER stress pathway and the RSR, in Stx induced cell death, and it is hypothesized 
that these pathways contribute to kidney cell death by causing apoptosis. 
Apoptosis as a result of ER stress signaling following Stx1 challenge has been 
demonstrated in vitro (127, 132), and mRNA up-regulation of the RSR defining 
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markers C-Fos and C-Jun has been demonstrated after in vitro Stx1 challenge 
(135). In vivo data suggest that apoptosis occurs during Stx-induced kidney 
injury, as renal cortices from EHEC-infected mice and children with D+HUS 
demonstrate TUNEL stained cells (30). If cell stress pathways and apoptosis are 
playing roles in Stx2 mediated lethal kidney injury in vivo, then down-regulation of 
these processes may have therapeutic benefit.  
Kidneys from Stx2 challenged animals euthanized at various time points, 
and from C. rodentium challenged animals euthanized upon reaching euthanasia 
criteria, were processed for analysis of mRNA expression of UPR markers 
spliced XBP1 and HSP40, ER stress marker CHOP, and anti- and pro- apoptotic 
markers Bcl2 and DR5. ER stress was down-regulated in Stx2- and Stx2-
producing C. rodentium challenged animals by co-treatment with 20 µg of anti-
coagulant and cytoprotective APC (I.P.; daily through day 3), which has been 
shown to down-regulate thapsigargin-induced ER stress in vitro (137). The 
MAP3K ZAK is hypothesized to be the MAP3K that transduces the signal from 
the damaged ribosome to the SAPK JNK following Stx2 cytotoxicity, and down-
regulation of the RSR was performed by co-treatment of Stx2 challenged animals 
with 625 µg of the kinase inhibitor Nilotinib (I.P.; daily through day 3) (136, 138). 
In order to down-regulate apoptosis, with or without down-regulation of ER 
stress, Stx2 challenged animals were co-treated with 125 µg of the pan-caspase 
inhibitor ZVAD (139), with or without APC. For all co-treatment experiments, 
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survival, kidney injury markers, and mRNA expression of ER stress and apoptotic 
markers were assayed.  
Kidney mRNA expression patterns of UPR, ER stress, and apoptotic 
markers were consistent with the work of Lee et al (127, 132), and confirmed that 
many of the UPR and ER stress markers identified as up-regulated following in 
vitro Stx1 challenge are similarly renally up-regulated in in vivo models of Stx2 
induced kidney injury. Though APC co-treatment was able to alter kidney mRNA 
expression of ER stress marker CHOP and anti-apoptosis marker Bcl2 in both 
murine models of Stx2 induced kidney injury, and provided a slight survival 
benefit, APC co-treatment neither altered kidney mRNA expression of DR5 nor 
rescued animals from Stx2 induced lethal kidney injury. These results led us to 
hypothesize that the continued renal DR5 pro-apoptotic signaling was potentially 
driving the Stx2 lethality in APC co-treated mice. Nilotinib co-treatment of Stx2 
challenged animals did not alter kidney mRNA expression of Bcl2 and DR5, nor 
were any kidney injury markers altered, suggesting that the RSR was neither 
driving renal DR5 mRNA up-regulation nor mediating Stx2 induced kidney injury 
in a major way. Co-treatment with the pan-caspase inhibitor ZVAD, either alone 
or with APC, did not rescue animals from lethal kidney injury. Taken together, 
these data are not consistent with a major role for ER stress induced apoptosis in 
Stx2 induced lethal kidney injury.  
The above described data, when taken with observations made by others, 
provide insight into intracellular Stx2 signaling that mediates Stx2-induced cell 
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death. It is thought that cellular surface expression of the Stx receptor Gb3 is the 
primary factor in determining a cell’s Stx sensitivity; however, evidence suggests 
that heterogeneity in the ceramide fatty acid chain length (176) and Gb3 density 
in lipid rafts (177), may also play important roles. Several AB5 holotoxins (129, 
130), including Stx (131), share a requirement for retrograde transport from the 
cell membrane to the ER for toxic activity, and in vitro data suggests that  
glucosylceramide availability plays a crucial role in intracellular Stx trafficking 
(156). Toxin did not associate with the detergent resistant membranes of the ER 
without adequate glucosylceramide, and neither translocation across the ER 
membrane nor cytotoxicity occurred under these conditions, suggesting that toxin 
sequestration within ER lipid rafts is required for translocation across the ER 
membrane, and that translocation across the ER membrane is required for 
cytotoxicity.  
In support of this hypothesis is the work of Bergan et al, which described 
in vitro protection from Stx1 and Stx2 cytotoxicity by the ether lipid precursor 
hexadecylglycerol (HG) (178). Modest reduction in toxin binding was observed in 
HG-treated cells, however toxin endocytosis and transport to the Golgi was 
unaltered, and the described protection was attributed to inhibition of toxin 
transport from the Golgi to the ER. HG was not protective against other toxins 
including ricin and cholera, suggesting that general retrograde translocation is 
not affected by HG; rather, Bergan et al hypothesized that HG is affecting the 
cellular lipidome, that the altered lipidome is affecting Stx retro-translocation to 
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the ER, and that the inability of Stx to translocate to the ER abolishes its 
cytotoxic activity. Work by Nishikawa et al and Stearns-Kurosawa et al also 
supports the hypothesis that interference with Stx retro-translocation may provide 
therapeutic benefit, as they demonstrated that treatment with therapeutic TVP, 
which interferes with Stx transport to the ER, rescued mice (152) and non-human 
primates (153) from EHEC and Stx2 challenge, respectively.  
HG is well tolerated by humans and animals (179). If the cellular lipidome 
plays a role in either Stx transport from the Golgi to the ER or across the ER 
membrane to the cytoplasm, and if these processes are crucial for Stx 
cytotoxicity (and thus, presumably, Stx mediated lethal kidney injury), then down-
regulation of these processes may provide therapeutic benefit. Future 
experiments to test what roles the cellular lipidome plays in in vivo Stx2 induced 
kidney injury may include co-treatment of either Stx2- or Stx2-producing C. 
rodentium challenged mice with HG.  
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